| 1 | Long-term clinical outcomes in early rheumatoid arthritis that was treated-to-target in the BeSt and IMPROVED studies | 1.9 | 13 | Citations (PDF) |
| 2 | Multitiered Proteome Analysis Displays the Hyperpermeability of the Rheumatoid Synovial Compartment for Plasma Proteins | 3.0 | 3 | Citations (PDF) |
| 3 | Distinct clinical outcomes based on multiple serum cytokine and chemokine profiles rather than autoantibody profiles and ultrasound findings in rheumatoid arthritis: a prospective ultrasound cohort study | 3.9 | 5 | Citations (PDF) |
| 4 | Rheumatoid arthritis-associated cervical spine deformity and flares in disease activity | 0.2 | 1 | Citations (PDF) |
| 5 | Variable domain glycosylation as a marker and modulator of immune responses: Insights into autoimmunity and B-cell malignancies | 6.7 | 1 | Citations (PDF) |
| 6 | Prolonged glucocorticoid use and rheumatoid arthritis-associated cervical spine deformity | 2.2 | 1 | Citations (PDF) |
| 7 | Rheumatoid arthritis-associated interstitial lung disease in countries across the world | 3.8 | 2 | Citations (PDF) |
| 8 | Time-independent disease state identification defines distinct trajectories determined by localised vs systemic inflammation in patients with early rheumatoid arthritis | 6.9 | 9 | Citations (PDF) |
| 9 | Interferon signatures fuel B cell hyperactivity and plasmablast expansion in systemic lupus erythematosus | 6.6 | 9 | Citations (PDF) |
| 10 | Initial glucocorticoid bridging in rheumatoid arthritis: does it affect glucocorticoid use over time? | 6.9 | 15 | Citations (PDF) |
| 11 | IgM antibodies against acetylated proteins as a possible starting point of the anti-modified protein antibody response in rheumatoid arthritis | 6.9 | 6 | Citations (PDF) |
| 12 | Long-term mortality in treated-to-target RA and UA: results of the BeSt and IMPROVED cohort | 6.9 | 12 | Citations (PDF) |
| 13 | Can Pharmacological Conditioning as an Add-On Treatment Optimize Standard Pharmacological Treatment in Patients with Recent-Onset Rheumatoid Arthritis? A Proof-of-Principle Randomized Clinical Trial | 4.2 | 0 | Citations (PDF) |
| 14 | Risk Factors for Antiphospholipid Antibodies and Antiphospholipid Syndrome | 2.5 | 10 | Citations (PDF) |
| 15 | Antigen-specific Fab profiling achieves molecular-resolution analysis of human autoantibody repertoires in rheumatoid arthritis | 13.7 | 24 | Citations (PDF) |
| 16 | Does a history of smoking increase the risk of developing systemic sclerosis? Insights from the Leiden Combined Care in Systemic Sclerosis cohort | 0.7 | 0 | Citations (PDF) |
| 17 | Prednisone use, disease activity and the occurrence of hyperglycaemia and diabetes in patients with early rheumatoid arthritis: a 10-year subanalysis of the BeSt study | 3.9 | 6 | Citations (PDF) |
| 18 | Untangling the relationship between smoking and systemic sclerosis: an analysis of the EUSTAR cohort | 3.9 | 4 | Citations (PDF) |
| 19 | Troponin I levels in systemic sclerosis patients with myocardial involvement | 1.8 | 2 | Citations (PDF) |
| 20 | Detection of Systemic Sclerosis-associated Interstitial Lung Disease by Exhaled Breath Analysis Using Electronic Nose Technology | 8.9 | 6 | Citations (PDF) |
| 21 | Are poor prognostic factors a realistic basis for treatment decisions in patients with rheumatoid arthritis? Lessons from the IMPROVED study | 3.9 | 4 | Citations (PDF) |
| 22 | Nipocalimab, an anti-FcRn monoclonal antibody, in participants with moderate to severe active rheumatoid arthritis and inadequate response or intolerance to anti-TNF therapy: results from the phase 2a IRIS-RA study | 3.9 | 20 | Citations (PDF) |
| 23 | Infliximab biosimilar GP1111: a review of 5 years’ post-approval experience | 3.0 | 2 | Citations (PDF) |
| 24 | Acetylated bacterial proteins as potent antigens inducing an anti-modified protein antibody response | 3.9 | 2 | Citations (PDF) |
| 25 | Circulating levels of endogenous complement inhibitors correlate inversely with complement consumption in systemic lupus erythematosus | 3.1 | 2 | Citations (PDF) |
| 26 | Pathogenic role of anti‐nuclear autoantibodies in systemic sclerosis: Insights from other rheumatic diseases | 6.4 | 6 | Citations (PDF) |
| 27 | Autoreactive B cells remain active despite clinical disease control in rheumatoid arthritis | 6.6 | 7 | Citations (PDF) |
| 28 | A genome-wide association analysis reveals new pathogenic pathways in gout | 25.2 | 80 | Citations (PDF) |
| 29 | Is AI-assisted active learning software able to reliably speed-up systematic literature reviews in rheumatology? A real-time comparison of AI-assisted and manual abstract selection | 3.9 | 1 | Citations (PDF) |
| 30 | NT-proBNP and sRAGE levels in early rheumatoid arthritis | 1.4 | 4 | Citations (PDF) |
| 31 | The effect of silver fibre gloves on Raynaud’s phenomenon in patients with systemic sclerosis: a double-blind randomized crossover trial | 1.9 | 8 | Citations (PDF) |
| 32 | High Prevalence but Low Impact of Cognitive Dysfunction on Quality of Life in Patients With Lupus and Neuropsychiatric Symptoms | 2.8 | 11 | Citations (PDF) |
| 33 | Autoreactive B cell responses targeting nuclear antigens in systemic sclerosis: Implications for disease pathogenesis | 3.8 | 14 | Citations (PDF) |
| 34 | Mouth opening in systemic sclerosis: Its course over time, determinants and impact on mouth handicap | 1.8 | 5 | Citations (PDF) |
| 35 | Inducibility or predestination? Queries and concepts around drug-free remission in rheumatoid arthritis | 3.5 | 8 | Citations (PDF) |
| 36 | Individual patient data meta-analysis on continued use of glucocorticoids after their initiation as bridging therapy in patients with rheumatoid arthritis | 6.9 | 21 | Citations (PDF) |
| 37 | Frequency of joint inflammation is associated with local joint damage progression in rheumatoid arthritis despite long-term targeted treatment | 3.9 | 7 | Citations (PDF) |
| 38 | Progression from suspected to definite systemic sclerosis and the role of anti-topoisomerase I antibodies | 3.9 | 7 | Citations (PDF) |
| 39 | Clinical Efficacy of Sarilumab Versus Upadacitinib Over 12 weeks: An Indirect Treatment Comparison | 2.0 | 1 | Citations (PDF) |
| 40 | Patterns of clinical joint inflammation in juvenile idiopathic arthritis | 3.9 | 10 | Citations (PDF) |
| 41 | Whole body insulin sensitivity is increased in systemic sclerosis | 2.3 | 6 | Citations (PDF) |
| 42 | Step forward in early recognition of systemic sclerosis: data from the Leiden CCISS cohort | 3.9 | 9 | Citations (PDF) |
| 43 | Repair of joint damage in patients with rheumatoid arthritis does not relate to previous suppression of inflammation: a subanalysis after 8 years treat-to-target in the BeSt-trial | 3.9 | 2 | Citations (PDF) |
| 44 | The long-term course of the Health Assessment Questionnaire in patients with systemic sclerosis | 1.8 | 4 | Citations (PDF) |
| 45 | Anti-topoisomerase, but not anti-centromere B cell responses in systemic sclerosis display active, Ig-secreting cells associated with lung fibrosis | 3.9 | 15 | Citations (PDF) |
| 46 | Anti-carbamylated protein antibodies in systemic sclerosis | 3.9 | 2 | Citations (PDF) |
| 47 | Antibodies against advanced glycation end-products and malondialdehyde-acetaldehyde adducts identify a new specific subgroup of hitherto patients with seronegative arthritis with a distinct clinical phenotype and an HLA class II association | 3.9 | 7 | Citations (PDF) |
| 48 | Treatment innovation for patients: a collaborative network in the Benelux and an inside view of 20 years of Galapagos | 1.4 | 5 | Citations (PDF) |
| 49 | Evolution of Systemic Sclerosis–Associated Interstitial Lung Disease One Year After Hematopoietic Stem Cell Transplantation or Cyclophosphamide | 2.8 | 19 | Citations (PDF) |
| 50 | Increasing incidence of autoantibody-negative RA is replicated and is partly explained by an aging population | 6.9 | 26 | Citations (PDF) |
| 51 | Joint inflammation tends to recur in the same joints during the rheumatoid arthritis disease course | 6.9 | 29 | Citations (PDF) |
| 52 | Neuropsychiatric systemic lupus erythematosus is associated with a distinct type and shape of cerebral white matter hyperintensities | 1.9 | 13 | Citations (PDF) |
| 53 | A framework for employing longitudinally collected multicenter electronic health records to stratify heterogeneous patient populations on disease history | 3.5 | 12 | Citations (PDF) |
| 54 | To treat or not to treat with immunosuppressive therapy: psychiatric disorders in patients with systemic lupus erythematosus | 2.3 | 2 | Citations (PDF) |
| 55 | Optical imaging compared to clinical examination in 484 rheumatoid arthritis patients: the Leeuwarden Handscan Registry | 2.4 | 4 | Citations (PDF) |
| 56 | Management of contemporary early undifferentiated arthritis: data on EULAR’s recommendation on the risk of persistent disease | 6.9 | 6 | Citations (PDF) |
| 57 | IgG Anti–Citrullinated Protein Antibody Variable Domain Glycosylation Increases Before the Onset of Rheumatoid Arthritis and Stabilizes Thereafter: A Cross‐Sectional Study Encompassing ~1,500 Samples | 6.1 | 51 | Citations (PDF) |
| 58 | MRI-Based Classification of Neuropsychiatric Systemic Lupus Erythematosus Patients With Self-Supervised Contrastive Learning | 2.7 | 21 | Citations (PDF) |
| 59 | Gastrointestinal symptom severity and progression in systemic sclerosis | 1.9 | 18 | Citations (PDF) |
| 60 | In rheumatoid arthritis patients, total IgA1 and IgA2 levels are elevated: implications for the mucosal origin hypothesis | 1.9 | 15 | Citations (PDF) |
| 61 | Surface Ig variable domain glycosylation affects autoantigen binding and acts as threshold for human autoreactive B cell activation | 10.9 | 71 | Citations (PDF) |
| 62 | Systematic literature review of observational cohorts and clinical trials into the success rate of glucocorticoid discontinuation after their use as bridging therapy in patients with rheumatoid arthritis | 6.9 | 19 | Citations (PDF) |
| 63 | Autoantibodies against specific post-translationally modified proteins are present in patients with lupus and associate with major neuropsychiatric manifestations | 3.9 | 14 | Citations (PDF) |
| 64 | Rheumatic?—A Digital Diagnostic Decision Support Tool for Individuals Suspecting Rheumatic Diseases: A Multicenter Pilot Validation Study | 2.4 | 15 | Citations (PDF) |
| 65 | Health-related quality of life in patients with mixed connective tissue disease: a comparison with matched systemic sclerosis patients | 3.1 | 5 | Citations (PDF) |
| 66 | ACPA-negative and ACPA-positive RA patients achieving disease resolution demonstrate distinct patterns of MRI-detected joint-inflammation | 1.9 | 10 | Citations (PDF) |
| 67 | Multi-ancestry genome-wide association analyses identify novel genetic mechanisms in rheumatoid arthritis | 25.2 | 327 | Citations (PDF) |
| 68 | Tract-based white matter hyperintensity patterns in patients with systemic lupus erythematosus using an unsupervised machine learning approach | 3.4 | 12 | Citations (PDF) |
| 69 | Baseline serum levels of cross-linked carboxy-terminal telopeptide of type I collagen predict abatacept treatment response in methotrexate-naive, anticitrullinated protein antibody-positive patients with early rheumatoid arthritis | 3.9 | 4 | Citations (PDF) |
| 70 | Shrinking Lung Syndrome | 1.5 | 8 | Citations (PDF) |
| 71 | Association Between Centromere- and Topoisomerase-specific Immune Responses and the Degree of Microangiopathy in Systemic Sclerosis | 2.3 | 10 | Citations (PDF) |
| 72 | Contribution of Sex and Autoantibodies to Microangiopathy Assessed by Nailfold Videocapillaroscopy in Systemic Sclerosis: A Systematic Review of the Literature | 2.8 | 6 | Citations (PDF) |
| 73 | Association Between Bone Mineral Density and Autoantibodies in Patients With Rheumatoid Arthritis | 6.1 | 28 | Citations (PDF) |
| 74 | Quantitative susceptibility mapping in the thalamus and basal ganglia of systemic lupus erythematosus patients with neuropsychiatric complaints | 3.3 | 8 | Citations (PDF) |
| 75 | Health-related quality of life in patients with systemic sclerosis: evolution over time and main determinants | 1.9 | 53 | Citations (PDF) |
| 76 | Earlier chronotype in patients with rheumatoid arthritis | 2.2 | 14 | Citations (PDF) |
| 77 | Phenotype and treatment of elderly onset compared with younger onset rheumatoid arthritis patients in international daily practice | 1.9 | 18 | Citations (PDF) |
| 78 | Fatigue in patients with systemic lupus erythematosus and neuropsychiatric symptoms is associated with anxiety and depression rather than inflammatory disease activityLupus, 2021, 30, 1124-1132 | 1.7 | 34 | Citations (PDF) |
| 79 | Light chain skewing in autoantibodies and B-cell receptors of the citrullinated antigen-binding B-cell response in rheumatoid arthritis | 2.3 | 9 | Citations (PDF) |
| 80 | Different phenotypes of neuropsychiatric systemic lupus erythematosus are related to a distinct pattern of structural changes on brain MRI | 3.6 | 23 | Citations (PDF) |
| 81 | Anticentromere Antibody Levels and Isotypes and the Development of Systemic Sclerosis | 6.1 | 29 | Citations (PDF) |
| 82 | Glucocorticoid discontinuation in patients with early rheumatoid and undifferentiated arthritis: a post-hoc analysis of the BeSt and IMPROVED studies | 6.9 | 15 | Citations (PDF) |
| 83 | New risk model is able to identify patients with a low risk of progression in systemic sclerosis | 3.9 | 9 | Citations (PDF) |
| 84 | Handwork vs machine: a comparison of rheumatoid arthritis patient populations as identified from EHR free-text by diagnosis extraction through machine-learning or traditional criteria-based chart review | 3.9 | 25 | Citations (PDF) |
| 85 | White matter hyperintensities associate with cognitive slowing in patients with systemic lupus erythematosus and neuropsychiatric symptoms | 3.9 | 15 | Citations (PDF) |
| 86 | A Polymorphism in C-C Chemokine Receptor 5 (CCR5) Associates with Löfgren’s Syndrome and Alters Receptor Expression as well as Functional Response | 4.6 | 5 | Citations (PDF) |
| 87 | Cross-reactivity of IgM anti-modified protein antibodies in rheumatoid arthritis despite limited mutational load | 3.9 | 20 | Citations (PDF) |
| 88 | Disease progression in systemic sclerosis | 1.9 | 13 | Citations (PDF) |
| 89 | Dissociation in SLE: A part of lupus fog?Lupus, 2021, 30, 2151-2156 | 1.7 | 2 | Citations (PDF) |
| 90 | Longitudinal changes in cerebral white matter microstructure in newly diagnosed systemic lupus erythematosus patients | 1.9 | 18 | Citations (PDF) |
| 91 | Evolution of anti-modified protein antibody responses can be driven by consecutive exposure to different post-translational modifications | 3.9 | 14 | Citations (PDF) |
| 92 | Sex hormones and sex hormone-targeting therapies in systemic sclerosis: A systematic literature review | 3.8 | 25 | Citations (PDF) |
| 93 | An overview of autoantibodies in rheumatoid arthritis | 6.6 | 348 | Citations (PDF) |
| 94 | Persistently activated, proliferative memory autoreactive B cells promote inflammation in rheumatoid arthritis | 12.5 | 99 | Citations (PDF) |
| 95 | Mortality in patients with systemic lupus erythematosus and neuropsychiatric involvement: A retrospective analysis from a tertiary referral center in the NetherlandsLupus, 2020, 29, 1892-1901 | 1.7 | 28 | Citations (PDF) |
| 96 | Changes in selected haematological parameters associated with JAK1/JAK2 inhibition observed in patients with rheumatoid arthritis treated with baricitinib | 3.9 | 38 | Citations (PDF) |
| 97 | Enhanced treatment strategies and distinct disease outcomes among autoantibody-positive and -negative rheumatoid arthritis patients over 25 years: A longitudinal cohort study in the Netherlands | 8.0 | 88 | Citations (PDF) |
| 98 | Earlier is better when treating rheumatoid arthritis: but can we detect a window of opportunity? | 3.9 | 23 | Citations (PDF) |
| 99 | Predictive factors for treatment-related mortality and major adverse events after autologous haematopoietic stem cell transplantation for systemic sclerosis: results of a long-term follow-up multicentre study | 6.9 | 50 | Citations (PDF) |
| 100 | Using genetics to prioritize diagnoses for rheumatology outpatients with inflammatory arthritis | 12.5 | 51 | Citations (PDF) |
| 101 | Body mass index and treatment survival in patients with RA starting treatment with TNFα-inhibitors: long-term follow-up in the real-life METEOR registry | 3.9 | 8 | Citations (PDF) |
| 102 | Association of Anti–Topoisomerase I Antibodies of the IgM Isotype With Disease Progression in Anti–Topoisomerase I–Positive Systemic Sclerosis | 6.1 | 41 | Citations (PDF) |
| 103 | Left Ventricular Systolic Function in Patients with Systemic Lupus Erythematosus and Its Association with Cardiovascular Events | 3.4 | 32 | Citations (PDF) |
| 104 | Antibodies and B cells recognising citrullinated proteins display a broad cross-reactivity towards other post-translational modifications | 6.9 | 117 | Citations (PDF) |
| 105 | Illness perceptions, risk perceptions and worries in patients with early systemic sclerosis: A focus group study | 1.6 | 7 | Citations (PDF) |
| 106 | On using machine learning algorithms to define clinically meaningful patient subgroups | 6.9 | 4 | Citations (PDF) |
| 107 | Disruptive innovation in rheumatology: new networks of global public–private partnerships are needed to take advantage of scientific progress | 6.9 | 2 | Citations (PDF) |
| 108 | Substitution of the quantitative serological component in the 2010 criteria for RA with qualitative presence of three autoantibodies yields similar performance: response to the article by Regueiro et al. | 3.9 | 4 | Citations (PDF) |
| 109 | Adalimumab Biosimilars in the Treatment of Rheumatoid Arthritis: A Systematic Review of the Evidence for Biosimilarity | 2.0 | 52 | Citations (PDF) |
| 110 | Clinicogenomic factors of biotherapy immunogenicity in autoimmune disease: A prospective multicohort study of the ABIRISK consortium | 8.0 | 55 | Citations (PDF) |
| 111 | One year in review 2020: novelties in the treatment of rheumatoid arthritis | 3.1 | 37 | Citations (PDF) |
| 112 | Degree of Vasculopathy in Systemic Sclerosis Patients with Anti-U3RNP Antibody Indicates Need for Extensive Cardiopulmonary Screening | 2.3 | 0 | Citations (PDF) |
| 113 | Prognostic properties of anti-topoisomerase antibodies in patients identified by the ACR/EULAR 2013 systemic sclerosis criteria | 1.9 | 14 | Citations (PDF) |
| 114 | In rheumatoid arthritis, changes in autoantibody levels reflect intensity of immunosuppression, not subsequent treatment response | 3.9 | 51 | Citations (PDF) |
| 115 | Different classes of anti-modified protein antibodies are induced on exposure to antigens expressing only one type of modification | 6.9 | 45 | Citations (PDF) |
| 116 | N‐Linked Glycans in the Variable Domain of IgG Anti–Citrullinated Protein Antibodies Predict the Development of Rheumatoid Arthritis | 6.1 | 115 | Citations (PDF) |
| 117 | Does treatment strategy influence the ability to achieve and sustain DMARD-free remission in patients with RA? Results of an observational study comparing an intensified DAS-steered treatment strategy with treat to target in routine care | 3.9 | 8 | Citations (PDF) |
| 118 | ACPA-negative RA consists of subgroups: patients with high likelihood of achieving sustained DMARD-free remission can be identified by serological markers at disease presentation | 3.9 | 24 | Citations (PDF) |
| 119 | Re-treatment with abatacept plus methotrexate for disease flare after complete treatment withdrawal in patients with early rheumatoid arthritis: 2-year results from the AVERT study | 3.9 | 9 | Citations (PDF) |
| 120 | Association of response to TNF inhibitors in rheumatoid arthritis with quantitative trait loci for CD40 and CD39 | 6.9 | 33 | Citations (PDF) |
| 121 | Progression of Left Ventricular Myocardial Dysfunction in Systemic Sclerosis: A Speckle-tracking Strain Echocardiography Study | 2.3 | 26 | Citations (PDF) |
| 122 | Identification of regulators of the myofibroblast phenotype of primary dermal fibroblasts from early diffuse systemic sclerosis patients | 3.4 | 42 | Citations (PDF) |
| 123 | Impact of the combined presence of erosions and ACPA on rheumatoid arthritis disease activity over time: results from the METEOR registry | 3.9 | 6 | Citations (PDF) |
| 124 | Circulating calprotectin (S100A8/A9) is higher in rheumatoid arthritis patients that relapse within 12 months of tapering anti-rheumatic drugs | 3.9 | 27 | Citations (PDF) |
| 125 | How to prevent, minimize, or extinguish nocebo effects in pain: a narrative review on mechanisms, predictors, and interventions | 2.5 | 68 | Citations (PDF) |
| 126 | Autoantibody status is not associated with early treatment response to first-line methotrexate in patients with early rheumatoid arthritis | 1.9 | 16 | Citations (PDF) |
| 127 | Autoantibody Development under Treatment with Immune-Checkpoint Inhibitors | 4.2 | 160 | Citations (PDF) |
| 128 | Incidence and risk factors for adalimumab and infliximab anti-drug antibodies in rheumatoid arthritis: A European retrospective multicohort analysis | 3.8 | 55 | Citations (PDF) |
| 129 | Depression and anxiety associate with less remission after 1 year in rheumatoid arthritis | 6.9 | 33 | Citations (PDF) |
| 130 | Is current smoking status and its relationship to anti-cyclic citrullinated peptide antibodies a predictor of worse response to biological therapies in rheumatoid arthritis patients? | 1.4 | 8 | Citations (PDF) |
| 131 | Conversion to seronegative status after abatacept treatment in patients with early and poor prognostic rheumatoid arthritis is associated with better radiographic outcomes and sustained remission: post hoc analysis of the AGREE study | 3.9 | 40 | Citations (PDF) |
| 132 | Dosing down with biologic therapies: a systematic review and clinicians’ perspective | 1.9 | 5 | Citations (PDF) |
| 133 | Anti-cyclic citrullinated peptide antibodies, other common autoantibodies, and smoking as risk factors for lymphoma in patients with rheumatoid arthritis | 1.4 | 3 | Citations (PDF) |
| 134 | The B cell response to citrullinated antigens in the development of rheumatoid arthritis | 25.5 | 104 | Citations (PDF) |
| 135 | Baseline autoantibody profile in rheumatoid arthritis is associated with early treatment response but not long-term outcomes | 3.9 | 50 | Citations (PDF) |
| 136 | Is optimising gout treatment the key to closing the mortality gap in gout patients? | 6.9 | 1 | Citations (PDF) |
| 137 | The extensive glycosylation of the ACPA variable domain observed for ACPA-IgG is absent from ACPA-IgM | 6.9 | 15 | Citations (PDF) |
| 138 | Clinical and radiological outcomes of 5-year drug-free remission-steered treatment in patients with early arthritis: IMPROVED study | 6.9 | 70 | Citations (PDF) |
| 139 | Etanercept in patients with inflammatory hand osteoarthritis (EHOA): a multicentre, randomised, double-blind, placebo-controlled trial | 6.9 | 157 | Citations (PDF) |
| 140 | An evidence-based approach to pre-pregnancy counselling for patients with systemic lupus erythematosus | 1.9 | 33 | Citations (PDF) |
| 141 | Fine-mapping and functional studies highlight potential causal variants for rheumatoid arthritis and type 1 diabetes | 25.2 | 142 | Citations (PDF) |
| 142 | Triple Positivity for Anti–Citrullinated Protein Autoantibodies, Rheumatoid Factor, and Anti–Carbamylated Protein Antibodies Conferring High Specificity for Rheumatoid Arthritis | 6.1 | 114 | Citations (PDF) |
| 143 | The anti-carbamylated protein antibody response is of overall low avidity despite extensive isotype switching | 1.9 | 12 | Citations (PDF) |
| 144 | MR signal intensity: staying on the bright side in MR image interpretation | 3.9 | 81 | Citations (PDF) |
| 145 | In RA, becoming seronegative over the first year of treatment does not translate to better chances of drug-free remission | 6.9 | 18 | Citations (PDF) |
| 146 | Two years of sarilumab in patients with rheumatoid arthritis and an inadequate response to MTX: safety, efficacy and radiographic outcomes | 1.9 | 35 | Citations (PDF) |
| 147 | Induction of sustained remission in early inflammatory arthritis with the combination of infliximab plus methotrexate: the DINORA trial | 3.9 | 23 | Citations (PDF) |
| 148 | Comparison between low disease activity or DAS remission as treatment target in patients with early active rheumatoid arthritis | 3.9 | 9 | Citations (PDF) |
| 149 | Structural Analysis of Variable Domain Glycosylation of Anti-Citrullinated Protein Antibodies in Rheumatoid Arthritis Reveals the Presence of Highly Sialylated Glycans | 3.0 | 100 | Citations (PDF) |
| 150 | The association between anti-carbamylated protein (anti-CarP) antibodies and radiographic progression in early rheumatoid arthritis: a study exploring replication and the added value to ACPA and rheumatoid factor | 6.9 | 78 | Citations (PDF) |
| 151 | Rheumatoid arthritis phenotype at presentation differs depending on the number of autoantibodies present | 6.9 | 43 | Citations (PDF) |
| 152 | Brief Report: Clinical Trials Aiming to Prevent Rheumatoid Arthritis Cannot Detect Prevention Without Adequate Risk Stratification: A Trial of Methotrexate Versus Placebo in Undifferentiated Arthritis as an Example | 6.1 | 52 | Citations (PDF) |
| 153 | Presence of anticitrullinated protein antibodies in a large population-based cohort from the Netherlands | 6.9 | 90 | Citations (PDF) |
| 154 | EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update | 6.9 | 3,511 | Citations (PDF) |
| 155 | Targeted lipidomics reveals activation of resolution pathways in knee osteoarthritis in humans | 5.5 | 76 | Citations (PDF) |
| 156 | Outcomes of neuropsychiatric events in systemic lupus erythematosus based on clinical phenotypes; prospective data from the Leiden NP SLE cohort | 1.7 | 27 | Citations (PDF) |
| 157 | Neuropsychiatric symptoms in systemic lupus erythematosus: impact on quality of lifeLupus, 2017, 26, 1252-1259 | 1.7 | 38 | Citations (PDF) |
| 158 | Dosing down with biologic therapies: a systematic review and clinicians’ perspective | 1.9 | 69 | Citations (PDF) |
| 159 | Protein array autoantibody profiles to determine diagnostic markers for neuropsychiatric systemic lupus erythematosus | 1.9 | 23 | Citations (PDF) |
| 160 | Evaluation of the diagnostic accuracy of hand and foot MRI for early Rheumatoid Arthritis | 1.9 | 35 | Citations (PDF) |
| 161 | Long-term mortality in patients with ST-segment elevation myocardial infarction is associated with anti-citrullinated protein antibodies | 2.2 | 14 | Citations (PDF) |
| 162 | Breach of autoreactive B cell tolerance by post-translationally modified proteins | 6.9 | 34 | Citations (PDF) |
| 163 | The role of autoantibodies in the pathophysiology of rheumatoid arthritis | 8.1 | 303 | Citations (PDF) |
| 164 | The prevalence of ACPA is lower in rheumatoid arthritis patients with an older age of onset but the composition of the ACPA response appears identical | 3.9 | 36 | Citations (PDF) |
| 165 | Differences in the symptomatic phase preceding ACPA-positive and ACPA-negative RA: a longitudinal study in arthralgia during progression to clinical arthritis | 6.9 | 73 | Citations (PDF) |
| 166 | Sustained remission in rheumatoid arthritis: latest evidence and clinical considerations | 3.5 | 132 | Citations (PDF) |
| 167 | SO037SIGNIFICANT REDUCTIONS OF PATHOGENIC AUTOANTIBODIES BY SYNERGETIC RITUXIMAB AND BELIMUMAB TREATMENT EFFECTIVELY INHIBITS NEUTROPHIL EXTRACELLULAR TRAPS IN SEVERE, REFRACTORY SLE - THE SYNBIOSE STUDY | 0.8 | 0 | Citations (PDF) |
| 168 | Do Comorbidities Play a Role in Hand Osteoarthritis Disease Burden? Data from the Hand Osteoarthritis in Secondary Care Cohort | 2.3 | 58 | Citations (PDF) |
| 169 | Rituximab in early systemic sclerosis | 3.9 | 63 | Citations (PDF) |
| 170 | Genomic Influences on Susceptibility and Severity of Rheumatoid Arthritis | 2.3 | 14 | Citations (PDF) |
| 171 | Molecular basis for increased susceptibility of Indigenous North Americans to seropositive rheumatoid arthritis | 6.9 | 55 | Citations (PDF) |
| 172 | MO040SYNERGETIC B-CELL IMMUNOMODULATION WITH RITUXIMAB AND BELIMUMAB IS CLINICALLY EFFECTIVE IN SEVERE AND REFRACTORY SYSTEMIC LUPUS ERYTHEMATOSUS - THE SYNBIOSE PROOF-OF-CONCEPT STUDY | 0.8 | 0 | Citations (PDF) |
| 173 | Evaluation of the joint distribution at disease presentation of patients with rheumatoid arthritis: a large study across continents | 3.9 | 18 | Citations (PDF) |
| 174 | Functional limitations in the phase of clinically suspect arthralgia are as serious as in early clinical arthritis; a longitudinal study | 3.9 | 29 | Citations (PDF) |
| 175 | Pathway Analysis to Identify Genetic Variants Associated with Efficacy of Adalimumab in Rheumatoid Arthritis | 1.5 | 7 | Citations (PDF) |
| 176 | Rheumatoid arthritis patients with continued low disease activity have similar outcomes over 10 years, regardless of initial therapy | 1.9 | 8 | Citations (PDF) |
| 177 | Phase 1b randomized, double-blind study of namilumab, an anti-granulocyte macrophage colony-stimulating factor monoclonal antibody, in mild-to-moderate rheumatoid arthritis | 3.9 | 35 | Citations (PDF) |
| 178 | Anti-citrullinated protein antibodies in the diagnosis of rheumatoid arthritis (RA): diagnostic performance of automated anti-CCP-2 and anti-CCP-3 antibodies assays | 2.2 | 38 | Citations (PDF) |
| 179 | Brain histopathology in patients with systemic lupus erythematosus: identification of lesions associated with clinical neuropsychiatric lupus syndromes and the role of complement | 1.9 | 131 | Citations (PDF) |
| 180 | Brief Report: The Role of Rare Protein‐Coding Variants in Anti–Tumor Necrosis Factor Treatment Response in Rheumatoid Arthritis | 6.1 | 8 | Citations (PDF) |
| 181 | Is the Site of Back Pain Related to the Location of Magnetic Resonance Imaging Lesions in Patients With Chronic Back Pain? Results From the Spondyloarthritis Caught Early Cohort | 2.8 | 23 | Citations (PDF) |
| 182 | Using a reference when defining an abnormal MRI reduces false-positive MRI results—a longitudinal study in two cohorts at risk for rheumatoid arthritis | 1.9 | 51 | Citations (PDF) |
| 183 | The isotype and IgG subclass distribution of anti-carbamylated protein antibodies in rheumatoid arthritis patients | 3.9 | 25 | Citations (PDF) |
| 184 | Similar short-term clinical response to high-dose versus low-dose methotrexate in monotherapy and combination therapy in patients with rheumatoid arthritis | 3.9 | 3 | Citations (PDF) |
| 185 | P5410Clinical and echocardiographic associates of all-cause mortality and cardiovascular outcomes in patients with systemic sclerosis | 2.2 | 0 | Citations (PDF) |
| 186 | Preventing progression from arthralgia to arthritis: targeting the right patients | 25.5 | 113 | Citations (PDF) |
| 187 | The Course of Bone Marrow Edema in Early Undifferentiated Arthritis and Rheumatoid Arthritis: A Longitudinal Magnetic Resonance Imaging Study at Bone Level | 6.1 | 58 | Citations (PDF) |
| 188 | The genetics of rheumatoid arthritis: risk and protection in different stages of the evolution of RA: Table 1 | 1.9 | 132 | Citations (PDF) |
| 189 | C1q Deficiency and Neuropsychiatric Systemic Lupus Erythematosus | 4.9 | 47 | Citations (PDF) |
| 190 | 079 Abatacept Plus Methotrexate can Effectively and Safely Regain the Target of Remission Following Re-Treatment for Flares after Drug-Free Withdrawal in Patients with Early Rheumatoid Arthritis | 1.9 | 0 | Citations (PDF) |
| 191 | The role of anticitrullinated protein antibodies in the early stages of rheumatoid arthritis | 3.6 | 21 | Citations (PDF) |
| 192 | Human mast cells costimulate T cells through a CD28‐independent interaction | 3.1 | 11 | Citations (PDF) |
| 193 | Therapeutic and diagnostic outcomes of a standardised, comprehensive care pathway for patients with systemic sclerosis | 3.9 | 53 | Citations (PDF) |
| 194 | Efficacy of etanercept in combination with methotrexate in moderate-to-severe rheumatoid arthritis is not dependent on methotrexate dosage | 3.9 | 12 | Citations (PDF) |
| 195 | Smoking is associated with the concurrent presence of multiple autoantibodies in rheumatoid arthritis rather than with anti-citrullinated protein antibodies per se: a multicenter cohort study | 3.9 | 57 | Citations (PDF) |
| 196 | Synovial fluid mononuclear cells provide an environment for long-term survival of antibody-secreting cells and promote the spontaneous production of anti-citrullinated protein antibodies | 6.9 | 31 | Citations (PDF) |
| 197 | TAC-TIC use of tacrolimus-based regimens in lupus nephritis | 2.3 | 27 | Citations (PDF) |
| 198 | Aesthetic dissatisfaction in patients with hand osteoarthritis and its impact on daily life | 1.4 | 13 | Citations (PDF) |
| 199 | Predictive factors of radiological progression after 2 years of remission-steered treatment in early arthritis patients: a post hoc analysis of the IMPROVED study | 3.9 | 15 | Citations (PDF) |
| 200 | When rheumatologists report that they agree with a guideline, does this mean that they practise the guideline in clinical practice? Results of the International Recommendation Implementation Study (IRIS) | 3.9 | 45 | Citations (PDF) |
| 201 | Body mass index and extent of MRI-detected inflammation: opposite effects in rheumatoid arthritis versus other arthritides and asymptomatic persons | 3.9 | 22 | Citations (PDF) |
| 202 | Sustained improvements in MRI outcomes with abatacept following the withdrawal of all treatments in patients with early, progressive rheumatoid arthritis | 6.9 | 19 | Citations (PDF) |
| 203 | Efficacy of tofacitinib monotherapy in methotrexate-naive patients with early or established rheumatoid arthritis | 3.9 | 30 | Citations (PDF) |
| 204 | Long-Term Outcomes of Patients With Recent-Onset Rheumatoid Arthritis After 10 Years of Tight Controlled Treatment | 9.6 | 113 | Citations (PDF) |
| 205 | Defining conditions where long-term glucocorticoid treatment has an acceptably low level of harm to facilitate implementation of existing recommendations: viewpoints from an EULAR task force | 6.9 | 311 | Citations (PDF) |
| 206 | The increased ability to present citrullinated peptides is not unique to HLA-SE molecules: arginine-to-citrulline conversion also enhances peptide affinity for HLA-DQ molecules | 3.9 | 28 | Citations (PDF) |
| 207 | Repeated FcεRI triggering reveals modified mast cell function related to chronic allergic responses in tissue | 6.1 | 23 | Citations (PDF) |
| 208 | Validity and responsiveness of the Michigan Hand Questionnaire in patients with systemic sclerosis | 1.9 | 27 | Citations (PDF) |
| 209 | The production and secretion of complement component C1q by human mast cells | 2.2 | 41 | Citations (PDF) |
| 210 | Older age is associated with more MRI-detected inflammation in hand and foot joints | 1.9 | 24 | Citations (PDF) |
| 211 | Sarilumab plus methotrexate improves patient-reported outcomes in patients with active rheumatoid arthritis and inadequate responses to methotrexate: results of a phase III trial | 3.9 | 63 | Citations (PDF) |
| 212 | Mast cell depletion in the preclinical phase of collagen-induced arthritis reduces clinical outcome by lowering the inflammatory cytokine profile | 3.9 | 31 | Citations (PDF) |
| 213 | Magnetic resonance imaging-detected inflammation is associated with functional disability in early arthritis—results of a cross-sectional study | 1.9 | 19 | Citations (PDF) |
| 214 | Crowdsourced assessment of common genetic contribution to predicting anti-TNF treatment response in rheumatoid arthritis | 13.7 | 78 | Citations (PDF) |
| 215 | Effectiveness of four dynamic treatment strategies in patients with anticitrullinated protein antibody-negative rheumatoid arthritis: a randomised trial | 3.9 | 13 | Citations (PDF) |
| 216 | Age affects joint space narrowing in patients with early active rheumatoid arthritis | 3.9 | 2 | Citations (PDF) |
| 217 | Evaluating Adherence to a Treat‐to‐Target Protocol in Recent‐Onset Rheumatoid Arthritis: Reasons for Compliance and Hesitation | 2.8 | 22 | Citations (PDF) |
| 218 | Two-year results of disease activity score (DAS)-remission-steered treatment strategies aiming at drug-free remission in early arthritis patients (the IMPROVED-study) | 3.9 | 44 | Citations (PDF) |
| 219 | Complement levels and anti-C1q autoantibodies in patients with neuropsychiatric systemic lupus erythematosus | 1.7 | 42 | Citations (PDF) |
| 220 | DAS steered therapy in clinical practice; cross-sectional results from the METEOR database | 2.1 | 2 | Citations (PDF) |
| 221 | Extensive glycosylation of ACPA-IgG variable domains modulates binding to citrullinated antigens in rheumatoid arthritis | 6.9 | 189 | Citations (PDF) |
| 222 | Disease-modifying antirheumatic drug-free sustained remission in rheumatoid arthritis: an increasingly achievable outcome with subsidence of disease symptoms | 6.9 | 77 | Citations (PDF) |
| 223 | Anticitrullinated protein antibodies and rheumatoid factor are associated with increased mortality but with different causes of death in patients with rheumatoid arthritis: a longitudinal study in three European cohorts | 6.9 | 65 | Citations (PDF) |
| 224 | Relationship of multi-biomarker disease activity score and other risk factors with radiographic progression in an observational study of patients with rheumatoid arthritis | 1.9 | 33 | Citations (PDF) |
| 225 | Glial and axonal changes in systemic lupus erythematosus measured with diffusion of intracellular metabolitesBrain, 2016, 139, 1447-1457 | 8.4 | 74 | Citations (PDF) |
| 226 | Evaluation of the association between anticarbamylated protein antibodies and the longitudinal course of functional ability in rheumatoid arthritis | 6.9 | 6 | Citations (PDF) |
| 227 | Protective effect of HLA-DRB1*13 alleles during specific phases in the development of ACPA-positive RA | 6.9 | 13 | Citations (PDF) |
| 228 | Clinical factors, anticitrullinated peptide antibodies and MRI-detected subclinical inflammation in relation to progression from clinically suspect arthralgia to arthritis | 6.9 | 165 | Citations (PDF) |
| 229 | Patients with chronic back pain of short duration from the SPACE cohort: which MRI structural lesions in the sacroiliac joints and inflammatory and structural lesions in the spine are most specific for axial spondyloarthritis? | 6.9 | 103 | Citations (PDF) |
| 230 | Identification and characterisation of citrullinated antigen-specific B cells in peripheral blood of patients with rheumatoid arthritis | 6.9 | 95 | Citations (PDF) |
| 231 | Rheumatologists’ adherence to a disease activity score steered treatment protocol in early arthritis patients is less if the target is remission | 2.2 | 11 | Citations (PDF) |
| 232 | 087 On Drug and Drug-Free Remission by Baseline Disease Duration in the Avert Trial: Abatacept Versus Methotrexate Comparison in Patients with Early Rheumatoid Arthritis | 1.9 | 1 | Citations (PDF) |
| 233 | A prediction model for progressive disease in systemic sclerosis | 3.9 | 9 | Citations (PDF) |
| 234 | Disease flares in rheumatoid arthritis are associated with joint damage progression and disability: 10-year results from the BeSt study | 3.9 | 107 | Citations (PDF) |
| 235 | Studies on ageing and the severity of radiographic joint damage in rheumatoid arthritis | 3.9 | 22 | Citations (PDF) |
| 236 | The specificity of anti-carbamylated protein antibodies for rheumatoid arthritis in a setting of early arthritis | 3.9 | 80 | Citations (PDF) |
| 237 | Reappraisal of the diagnostic and prognostic value of morning stiffness in arthralgia and early arthritis: results from the Groningen EARC, Leiden EARC, ESPOIR, Leiden EAC and REACH | 3.9 | 21 | Citations (PDF) |
| 238 | Anti-citrullinated protein antibodies contribute to platelet activation in rheumatoid arthritis | 3.9 | 79 | Citations (PDF) |
| 239 | Response to ‘Feasibility of tailored treatment based on risk stratification in patients with early rheumatoid arthritis’ – authors’ reply | 3.9 | 0 | Citations (PDF) |
| 240 | An investigation of the added value of an ACPA multiplex assay in an early rheumatoid arthritis setting | 3.9 | 22 | Citations (PDF) |
| 241 | Twenty-eight-week results from the REALISTIC phase IIIb randomized trial: efficacy, safety and predictability of response to certolizumab pegol in a diverse rheumatoid arthritis population | 3.9 | 18 | Citations (PDF) |
| 242 | Ability of Interleukin‐33– and Immune Complex–Triggered Activation of Human Mast Cells to Down‐Regulate Monocyte‐Mediated Immune Responses | 6.1 | 55 | Citations (PDF) |
| 243 | Comparative Efficacy of Novel DMARDs as Monotherapy and in Combination with Methotrexate in Rheumatoid Arthritis Patients with Inadequate Response to Conventional DMARDs: A Network Meta-Analysis | 1.1 | 91 | Citations (PDF) |
| 244 | Sarilumab Plus Methotrexate in Patients With Active Rheumatoid Arthritis and Inadequate Response to Methotrexate: Results of a Phase III Study | 6.1 | 245 | Citations (PDF) |
| 245 | Concordance between inflammation at physical examination and on MRI in patients with early arthritis | 6.9 | 54 | Citations (PDF) |
| 246 | Evaluating processes underlying the predictive value of baseline erosions for future radiological damage in early rheumatoid arthritis | 6.9 | 22 | Citations (PDF) |
| 247 | Percentage of patients with spondyloarthritis in patients referred because of chronic back pain and performance of classification criteria: experience from the Spondyloarthritis Caught Early (SPACE) cohort: Table 3 | 1.9 | 8 | Citations (PDF) |
| 248 | IL2RA is associated with persistence of rheumatoid arthritis | 3.9 | 24 | Citations (PDF) |
| 249 | Characterising arthralgia in the preclinical phase of rheumatoid arthritis using MRI | 6.9 | 113 | Citations (PDF) |
| 250 | Identification of a novel non-coding mutation in C1qB in a Dutch child with C1q deficiency associated with recurrent infections | 1.1 | 17 | Citations (PDF) |
| 251 | Continued Participation in a Ten‐Year Tight Control Treat‐to‐Target Study in Rheumatoid Arthritis: Why Keep Patients Doing their Best? | 2.8 | 10 | Citations (PDF) |
| 252 | Evaluating drug-free remission with abatacept in early rheumatoid arthritis: results from the phase 3b, multicentre, randomised, active-controlled AVERT study of 24 months, with a 12-month, double-blind treatment period | 6.9 | 233 | Citations (PDF) |
| 253 | Anti-carbamylated Protein Antibodies Are Present Prior to Rheumatoid Arthritis and Are Associated with Its Future Diagnosis | 2.3 | 129 | Citations (PDF) |
| 254 | Personalized medicine in rheumatoid arthritis: is the glass half full or half empty? | 7.3 | 16 | Citations (PDF) |
| 255 | A genetic study on C5-TRAF1 and progression of joint damage in rheumatoid arthritis | 3.9 | 149 | Citations (PDF) |
| 256 | The relative contribution of mechanical stress and systemic processes in different types of osteoarthritis: the NEO study | 6.9 | 199 | Citations (PDF) |
| 257 | Determinants of reaching drug-free remission in patients with early rheumatoid or undifferentiated arthritis after one year of remission-steered treatment | 1.9 | 13 | Citations (PDF) |
| 258 | Aiming for a simpler early arthritis MRI protocol: can Gd contrast administration be eliminated? | 3.6 | 46 | Citations (PDF) |
| 259 | Mortality in osteoarthritis patients | 1.4 | 33 | Citations (PDF) |
| 260 | Immunogenetics of rheumatoid arthritis: Understanding functional implications | 6.6 | 73 | Citations (PDF) |
| 261 | Genetic Factors for the Severity of ACPA-negative Rheumatoid Arthritis in 2 Cohorts of Early Disease: A Genome-wide Study | 2.3 | 27 | Citations (PDF) |
| 262 | Anti-carbamylated protein antibodies in rheumatoid arthritis patients of Asian descent: Fig. 1 | 1.9 | 25 | Citations (PDF) |
| 263 | Marked variability in clinical presentation and outcome of patients with C1q immunodeficiency | 6.6 | 42 | Citations (PDF) |
| 264 | A multimodal MRI approach to identify and characterize microstructural brain changes in neuropsychiatric systemic lupus erythematosus | 3.3 | 58 | Citations (PDF) |
| 265 | Association of Valine and Leucine at HLA–DRB1 Position 11 With Radiographic Progression in Rheumatoid Arthritis, Independent of the Shared Epitope Alleles but Not Independent of Anti–Citrullinated Protein Antibodies | 6.1 | 20 | Citations (PDF) |
| 266 | The diagnostic accuracy of the squeeze test to identify arthritis: a cross-sectional cohort study | 6.9 | 29 | Citations (PDF) |
| 267 | Anticarbamylated protein antibodies can be detected in animal models of arthritis that require active involvement of the adaptive immune system | 6.9 | 20 | Citations (PDF) |
| 268 | FcGRGenetic Polymorphisms and the Response to Adalimumab in Patients with Rheumatoid Arthritis | 1.5 | 32 | Citations (PDF) |
| 269 | IL-17-producing CD4+ T cells are increased in early, active axial spondyloarthritis including patients without imaging abnormalities | 1.9 | 54 | Citations (PDF) |
| 270 | Evaluation of Magnetic Resonance Imaging–Detected Tenosynovitis in the Hand and Wrist in Early Arthritis | 6.1 | 69 | Citations (PDF) |
| 271 | Fatigue in rheumatoid arthritis; a persistent problem: a large longitudinal study | 3.9 | 72 | Citations (PDF) |
| 272 | Impact of pulmonary fibrosis and elevated pulmonary pressures on right ventricular function in patients with systemic sclerosis | 1.9 | 4 | Citations (PDF) |
| 273 | Widespread non-additive and interaction effects within HLA loci modulate the risk of autoimmune diseases | 25.2 | 193 | Citations (PDF) |
| 274 | Clinical and radiographic outcomes at 2 years and the effect of tocilizumab discontinuation following sustained remission in the second and third year of the ACT-RAY study | 6.9 | 97 | Citations (PDF) |
| 275 | New data and an old puzzle: the negative association between schizophrenia and rheumatoid arthritis | 4.9 | 58 | Citations (PDF) |
| 276 | Abatacept decreases disease activity in the absence of CD4+ T cells in a collagen-induced arthritis model | 3.9 | 23 | Citations (PDF) |
| 277 | Quality indicators in rheumatoid arthritis: results from the METEOR database | 1.9 | 30 | Citations (PDF) |
| 278 | Anti-citrullinated protein antibodies acquire a pro-inflammatory Fc glycosylation phenotype prior to the onset of rheumatoid arthritis | 6.9 | 265 | Citations (PDF) |
| 279 | Predicting the severity of joint damage in rheumatoid arthritis; the contribution of genetic factors | 6.9 | 11 | Citations (PDF) |
| 280 | Integration of Sequence Data from a Consanguineous Family with Genetic Data from an Outbred Population Identifies PLB1 as a Candidate Rheumatoid Arthritis Risk Gene | 2.3 | 39 | Citations (PDF) |
| 281 | 87. Comparative Efficacy of Novel Disease-Modifying Antirheumatic Drugs as Monotherapy and in Combination with Methotrexate in Rheumatoid Arthritis Patients with an Inadequate Response to Traditional Dmards: A Network Meta-Analysis | 1.9 | 1 | Citations (PDF) |
| 282 | Differential methylation within the major histocompatibility complex region in rheumatoid arthritis: a replication study | 1.9 | 17 | Citations (PDF) |
| 283 | Autoimmunity: Break-through in the diagnosis and treatment of immune-mediated inflammatory diseases | 2.4 | 5 | Citations (PDF) |
| 284 | Are Baseline High Molecular Weight Adiponectin Levels Associated with Radiographic Progression in Rheumatoid Arthritis and Osteoarthritis? | 2.3 | 13 | Citations (PDF) |
| 285 | MRI-detected subclinical joint inflammation is associated with radiographic progression | 6.9 | 35 | Citations (PDF) |
| 286 | Does a Genetic Variant in FOXO3A Predict a Milder Course of Rheumatoid Arthritis? | 6.1 | 9 | Citations (PDF) |
| 287 | Belimumab after rituximab as maintenance therapy in lupus nephritis | 1.9 | 66 | Citations (PDF) |
| 288 | Five-year outcomes of probable rheumatoid arthritis treated with methotrexate or placebo during the first year (the PROMPT study) | 6.9 | 56 | Citations (PDF) |
| 289 | Feasibility of tailored treatment based on risk stratification in patients with early rheumatoid arthritis | 3.9 | 5 | Citations (PDF) |
| 290 | Are Rheumatoid Arthritis Patients Discernible from Other Early Arthritis Patients Using 1.5T Extremity Magnetic Resonance Imaging? A Large Cross-sectional Study | 2.3 | 25 | Citations (PDF) |
| 291 | Risk of rheumatoid arthritis development in patients with unclassified arthritis according to the 2010 ACR/EULAR criteria for rheumatoid arthritis | 1.9 | 0 | Citations (PDF) |
| 292 | Carbamylation and antibodies against carbamylated proteins in autoimmunity and other pathologies | 7.1 | 122 | Citations (PDF) |
| 293 | What is the evidence for the presence of a therapeutic window of opportunity in rheumatoid arthritis? A systematic literature review | 6.9 | 299 | Citations (PDF) |
| 294 | The pathogenic potential of autoreactive antibodies in rheumatoid arthritis | 8.1 | 26 | Citations (PDF) |
| 295 | Health care in systemic lupus erythematosus (SLE): the patient’s perspective | 2.2 | 12 | Citations (PDF) |
| 296 | Mortality in neuropsychiatric systemic lupus erythematosus (NPSLE) | 1.7 | 107 | Citations (PDF) |
| 297 | A Multibiomarker Disease Activity Score for Rheumatoid Arthritis Predicts Radiographic Joint Damage in the BeSt Study | 2.3 | 41 | Citations (PDF) |
| 298 | Low-avidity anticitrullinated protein antibodies (ACPA) are associated with a higher rate of joint destruction in rheumatoid arthritis | 6.9 | 45 | Citations (PDF) |
| 299 | Sarilumab, a fully human monoclonal antibody against IL-6Rα in patients with rheumatoid arthritis and an inadequate response to methotrexate: efficacy and safety results from the randomised SARIL-RA-MOBILITY Part A trial | 6.9 | 204 | Citations (PDF) |
| 300 | HLA-B60 and the HLA-B27/HLA-B60 genotype are not risk factors for acute anterior uveitis | 6.9 | 0 | Citations (PDF) |
| 301 | Clustering of hand osteoarthritis progression and its relationship to progression of osteoarthritis at the knee | 6.9 | 28 | Citations (PDF) |
| 302 | Long-term outcome of Rheumatoid Arthritis defined according to the 2010-classification criteria | 6.9 | 31 | Citations (PDF) |
| 303 | Aiming for a shorter rheumatoid arthritis MRI protocol: can contrast-enhanced MRI replace T2 for the detection of bone marrow oedema? | 3.6 | 37 | Citations (PDF) |
| 304 | Macrophage migration inhibitory factor (MIF) -173 polymorphism is associated with clinical erythema nodosum in Löfgren’s syndrome | 3.5 | 12 | Citations (PDF) |
| 305 | Is HLA-B27 Increased in Patients Diagnosed with Undifferentiated Arthritis? Results from the Leiden Early Arthritis Cohort | 2.3 | 1 | Citations (PDF) |
| 306 | IgE and IL‐33−mediated triggering of human basophils inhibits TLR4−induced monocyte activation | 3.1 | 36 | Citations (PDF) |
| 307 | Osteoarthritis development is induced by increased dietary cholesterol and can be inhibited by atorvastatin in APOE*3Leiden.CETP mice—a translational model for atherosclerosis | 6.9 | 86 | Citations (PDF) |
| 308 | Subclinical inflammation on MRI of hand and foot of anticitrullinated peptide antibody–negative arthralgia patients at risk for rheumatoid arthritis | 3.9 | 36 | Citations (PDF) |
| 309 | A genetic variant in osteoprotegerin is associated with progression of joint destruction in rheumatoid arthritis | 3.9 | 23 | Citations (PDF) |
| 310 | Fine Mapping Seronegative and Seropositive Rheumatoid Arthritis to Shared and Distinct HLA Alleles by Adjusting for the Effects of Heterogeneity | 6.5 | 170 | Citations (PDF) |
| 311 | Activation of human basophils by combined toll‐like receptor‐ and FcεRI‐triggering can promote Th2 skewing of naive T helper cells | 3.1 | 65 | Citations (PDF) |
| 312 | Tocilizumab in the Treatment of Rheumatoid Arthritis: A Cost-Effectiveness Analysis in the UK | 3.6 | 27 | Citations (PDF) |
| 313 | Identification of a genetic variant for joint damage progression in autoantibody-positive rheumatoid arthritis | 6.9 | 44 | Citations (PDF) |
| 314 | Anti-carbamylated protein (anti-CarP) antibodies precede the onset of rheumatoid arthritis | 6.9 | 209 | Citations (PDF) |
| 315 | Degree of synovitis on MRI by comprehensive whole knee semi-quantitative scoring method correlates with histologic and macroscopic features of synovial tissue inflammation in knee osteoarthritis | 5.5 | 61 | Citations (PDF) |
| 316 | Anti-CarP antibodies in two large cohorts of patients with rheumatoid arthritis and their relationship to genetic risk factors, cigarette smoking and other autoantibodies | 6.9 | 136 | Citations (PDF) |
| 317 | HLA and rheumatoid arthritis: How do they connect? | 3.8 | 29 | Citations (PDF) |
| 318 | Antibodies Specific for Carbamylated Proteins Precede the Onset of Clinical Symptoms in Mice with Collagen Induced Arthritis | 2.3 | 41 | Citations (PDF) |
| 319 | The relationship between disease activity and depressivesymptoms severity and optimism—results from the IMPROVED study | 2.2 | 12 | Citations (PDF) |
| 320 | An innovative care model coordinated by a physical therapist and nurse practitioner for osteoarthritis of the hip and knee in specialist care: a prospective study | 2.4 | 16 | Citations (PDF) |
| 321 | Circulating plasmablasts/plasmacells as a source of anticitrullinated protein antibodies in patients with rheumatoid arthritis | 6.9 | 74 | Citations (PDF) |
| 322 | Neuropsychiatric manifestations in patients with systemic lupus erythematosus: epidemiology and radiology pointing to an immune-mediated cause | 6.9 | 72 | Citations (PDF) |
| 323 | Magnetic resonance imaging of the sacroiliac joints in the early detection of spondyloarthritis: no added value of gadolinium compared with short tau inversion recovery sequence | 1.9 | 94 | Citations (PDF) |
| 324 | Demyelinating disease in SLE: Is it multiple sclerosis or lupus? | 3.9 | 54 | Citations (PDF) |
| 325 | Genome-wide association analysis of anti-TNF drug response in patients with rheumatoid arthritis | 6.9 | 100 | Citations (PDF) |
| 326 | DX5 +CD4 +T cells modulate CD4 +T‐cell response via inhibition of IL‐12 production by DCs | 3.1 | 4 | Citations (PDF) |
| 327 | In erosive hand osteoarthritis more inflammatory signs on ultrasound are found than in the rest of hand osteoarthritis | 6.9 | 74 | Citations (PDF) |
| 328 | Biologic and oral disease-modifying antirheumatic drug monotherapy in rheumatoid arthritis | 6.9 | 123 | Citations (PDF) |
| 329 | Epistasis between two HLA antigens defines a subset of individuals at a very high risk for ankylosing spondylitis | 6.9 | 38 | Citations (PDF) |
| 330 | Recognition of citrullinated and carbamylated proteins by human antibodies: specificity, cross-reactivity and the ‘AMC-Senshu’ method | 6.9 | 77 | Citations (PDF) |
| 331 | Concentration-controlled treatment of lupus nephritis with mycophenolate mofetil | 1.7 | 33 | Citations (PDF) |
| 332 | Association of High Body Mass Index With Decreased Treatment Response to Combination Therapy in Recent‐Onset Rheumatoid Arthritis Patients | 2.8 | 84 | Citations (PDF) |
| 333 | Association study of candidate genes for the progression of hand osteoarthritis | 5.5 | 27 | Citations (PDF) |
| 334 | Autoimmunity in rheumatoid arthritis: different antigens—common principles | 6.9 | 47 | Citations (PDF) |
| 335 | Personalized medicine: predicting responses to therapy in patients with RA | 3.8 | 30 | Citations (PDF) |
| 336 | MRI of hand and foot joints of patients with anticitrullinated peptide antibody positive arthralgia without clinical arthritis | 6.9 | 50 | Citations (PDF) |
| 337 | Drug therapy in undifferentiated arthritis: a systematic literature review | 6.9 | 35 | Citations (PDF) |
| 338 | ASAS modification of the Berlin algorithm for diagnosing axial spondyloarthritis: results from the SPondyloArthritis Caught Early (SPACE)-cohort and from the Assessment of SpondyloArthritis international Society (ASAS)-cohort | 6.9 | 139 | Citations (PDF) |
| 339 | ‘Insights in the relationship of joint space narrowing versus erosive joint damage and physical functioning of patients with RA‘ | 6.9 | 26 | Citations (PDF) |
| 340 | Genetic studies on components of the Wnt signalling pathway and the severity of joint destruction in rheumatoid arthritis | 6.9 | 83 | Citations (PDF) |
| 341 | The concentration of anticitrullinated protein antibodies in serum and synovial fluid in relation to total immunoglobulin concentrations | 6.9 | 28 | Citations (PDF) |
| 342 | Application of the 2010 ACR/EULAR classification criteria in patients with very early inflammatory arthritis: analysis of sensitivity, specificity and predictive values in the SAVE study cohort | 6.9 | 44 | Citations (PDF) |
| 343 | Evaluation of the contribution of cumulative levels of inflammation to the variance in joint destruction in rheumatoid arthritis | 6.9 | 13 | Citations (PDF) |
| 344 | Early Local Swelling and Tenderness Are Associated with Large-joint Damage After 8 Years of Treatment to Target in Patients with Recent-onset Rheumatoid Arthritis | 2.3 | 17 | Citations (PDF) |
| 345 | Comparison of methodologies for analysing the progression of joint destruction in rheumatoid arthritis | 1.4 | 29 | Citations (PDF) |
| 346 | Autonomous online health assessment questionnaire registry in daily clinical practice | 1.9 | 15 | Citations (PDF) |
| 347 | Pathogenic relevance of anti-citrullinated vimentin antibodies: Comment on the article by Montes et al | 6.1 | 0 | Citations (PDF) |
| 348 | Review: The Preclinical Phase of Rheumatoid Arthritis: What Is Acknowledged and What Needs to be Assessed? | 6.1 | 54 | Citations (PDF) |
| 349 | Brief Report: Anti–Carbamylated Protein Antibodies Are Present in Arthralgia Patients and Predict the Development of Rheumatoid Arthritis | 6.1 | 178 | Citations (PDF) |
| 350 | Patients with early arthritis consume less alcohol than controls, regardless of the type of arthritis | 1.9 | 16 | Citations (PDF) |
| 351 | Metabolic Profiling Reveals Differences in Concentrations of Oxylipins and Fatty Acids Secreted by the Infrapatellar Fat Pad of Donors With End‐Stage Osteoarthritis and Normal Donors | 6.1 | 54 | Citations (PDF) |
| 352 | Genome-Wide Association Study and Gene Expression Analysis Identifies CD84 as a Predictor of Response to Etanercept Therapy in Rheumatoid Arthritis | 3.2 | 160 | Citations (PDF) |
| 353 | An evaluation of molecular and clinical remission in rheumatoid arthritis by assessing radiographic progression | 1.9 | 65 | Citations (PDF) |
| 354 | Allele‐Dose Association of the C5orf30 rs26232 Variant With Joint Damage in Rheumatoid Arthritis | 6.1 | 25 | Citations (PDF) |
| 355 | Evaluating joint destruction in rheumatoid arthritis: is it necessary to radiograph both hands and feet? | 6.9 | 26 | Citations (PDF) |
| 356 | Serum Pyridinoline Levels and Prediction of Severity of Joint Destruction in Rheumatoid Arthritis | 2.3 | 18 | Citations (PDF) |
| 357 | Percentage of patients with spondyloarthritis in patients referred because of chronic back pain and performance of classification criteria: experience from the Spondyloarthritis Caught Early (SPACE) cohort | 1.9 | 171 | Citations (PDF) |
| 358 | Risk of rheumatoid arthritis development in patients with unclassified arthritis according to the 2010 ACR/EULAR criteria for rheumatoid arthritis | 1.9 | 30 | Citations (PDF) |
| 359 | Dr. Zirkzee, et al reply | 2.3 | 0 | Citations (PDF) |
| 360 | Risk Factors for Progression in Hand Osteoarthritis: A Systematic Review | 2.8 | 29 | Citations (PDF) |
| 361 | Communication between human mast cells and CD4+T cells through antigen‐dependent interactions | 3.1 | 58 | Citations (PDF) |
| 362 | Adding tocilizumab or switching to tocilizumab monotherapy in methotrexate inadequate responders: 24-week symptomatic and structural results of a 2-year randomised controlled strategy trial in rheumatoid arthritis (ACT-RAY) | 6.9 | 273 | Citations (PDF) |
| 363 | Platelets and autoimmunity | 3.0 | 107 | Citations (PDF) |
| 364 | Adipocyte‐derived lipids modulate CD4+ T‐cell function | 3.1 | 81 | Citations (PDF) |
| 365 | Improved early identification of arthritis: evaluating the efficacy of Early Arthritis Recognition Clinics | 6.9 | 41 | Citations (PDF) |
| 366 | Crowdsourcing genetic prediction of clinical utility in the Rheumatoid Arthritis Responder Challenge | 25.2 | 24 | Citations (PDF) |
| 367 | Reasons for medical help-seeking behaviour of patients with recent-onset arthralgia | 6.9 | 19 | Citations (PDF) |
| 368 | Genetics of rheumatoid arthritis contributes to biology and drug discovery | 37.9 | 2,325 | Citations (PDF) |
| 369 | Health-care utilization in Dutch systemic sclerosis patients | 2.2 | 13 | Citations (PDF) |
| 370 | Assessment of global disease activity in RA patients monitored in the METEOR database: the patient's versus the rheumatologist's opinion | 2.2 | 16 | Citations (PDF) |
| 371 | Profiling the Secretion of Soluble Mediators by End Stage Osteoarthritis Synovial Tissue Explants Reveals a Reduced Responsiveness to an Inflammatory Trigger | 2.3 | 4 | Citations (PDF) |
| 372 | Cytokine-Suppressive Anti-Inflammatory Drugs | 0.1 | 1 | Citations (PDF) |
| 373 | Genetic predisposition of the severity of joint destruction in rheumatoid arthritis: a population-based study | 6.9 | 68 | Citations (PDF) |
| 374 | Undifferentiated arthritis characteristics and outcomes when applying the 2010 and 1987 criteria for rheumatoid arthritis | 6.9 | 50 | Citations (PDF) |
| 375 | Novel genetic association of the VTCN1 region with rheumatoid arthritis | 6.9 | 13 | Citations (PDF) |
| 376 | Diagnostic value of performing chest x-rays in patients presenting with recent-onset arthritis | 6.9 | 2 | Citations (PDF) |
| 377 | Prospective Study of Clinical Phenotypes in Neuropsychiatric Systemic Lupus Erythematosus; Multidisciplinary Approach to Diagnosis and Therapy | 2.3 | 71 | Citations (PDF) |
| 378 | No impact of serum uric acid on the outcome of recent-onset arthritis | 6.9 | 6 | Citations (PDF) |
| 379 | Loss of metacarpal bone density predicts RA development in recent-onset arthritis | 1.9 | 39 | Citations (PDF) |
| 380 | Rapid radiological progression in the first year of early rheumatoid arthritis is predictive of disability and joint damage progression during 8 years of follow-up | 6.9 | 33 | Citations (PDF) |
| 381 | The ACPA recognition profile and subgrouping of ACPA-positive RA patients | 6.9 | 65 | Citations (PDF) |
| 382 | EULAR recommendations for terminology and research in individuals at risk of rheumatoid arthritis: report from the Study Group for Risk Factors for Rheumatoid Arthritis | 6.9 | 435 | Citations (PDF) |
| 383 | Remission induction therapy with methotrexate and prednisone in patients with early rheumatoid and undifferentiated arthritis (the IMPROVED study) | 6.9 | 95 | Citations (PDF) |
| 384 | Performance of classification criteria for peripheral spondyloarthritis and psoriatic arthritis in the Leiden early arthritis cohort | 6.9 | 48 | Citations (PDF) |
| 385 | Does the season at symptom onset influence the long-term severity of radiographic joint destruction in rheumatoid arthritis? | 6.9 | 9 | Citations (PDF) |
| 386 | Large-joint damage in patients with early rheumatoid arthritis and its association with treatment strategy and damage of the small joints | 1.9 | 22 | Citations (PDF) |
| 387 | Anti-citrullinated protein antibodies (ACPA) in early rheumatoid arthritis | 1.9 | 30 | Citations (PDF) |
| 388 | High-density genetic mapping identifies new susceptibility loci for rheumatoid arthritis | 25.2 | 619 | Citations (PDF) |
| 389 | Efficacy and safety of certolizumab pegol in a broad population of patients with active rheumatoid arthritis: results from the REALISTIC phase IIIb study | 1.9 | 118 | Citations (PDF) |
| 390 | The association of treatment response and joint damage with ACPA-status in recent-onset RA: a subanalysis of the 8-year follow-up of the BeSt study | 6.9 | 88 | Citations (PDF) |
| 391 | The influence of ACPA status and characteristics on the course of RA | 25.5 | 206 | Citations (PDF) |
| 392 | Risk factors for reported influenza and influenza-like symptoms in patients with rheumatoid arthritis | 1.4 | 22 | Citations (PDF) |
| 393 | Towards personalized treatment: predictors of short-term HAQ response in recent-onset active rheumatoid arthritis are different from predictors of rapid radiological progression | 1.4 | 11 | Citations (PDF) |
| 394 | Sustained drug-free remission in rheumatoid arthritis after DAS-driven or non-DAS-driven therapy: a comparison of two cohort studies | 1.9 | 40 | Citations (PDF) |
| 395 | The 2010 ACR/EULAR criteria for rheumatoid arthritis: do they affect the classification or diagnosis of rheumatoid arthritis? | 6.9 | 27 | Citations (PDF) |
| 396 | Prevalence of vertebral fractures in a disease activity steered cohort of patients with early active rheumatoid arthritis | 2.1 | 34 | Citations (PDF) |
| 397 | Clinical Pharmacogenetic Model to Predict Response of MTX Monotherapy in Patients with Established Rheumatoid Arthritis After DMARD Failure | 1.5 | 34 | Citations (PDF) |
| 398 | Synovial inflammation, immune cells and their cytokines in osteoarthritis: a review | 5.5 | 619 | Citations (PDF) |
| 399 | Induction of long-term B-cell depletion in refractory rheumatoid arthritis patients preferentially affects autoreactive more than protective humoral immunity | 3.9 | 49 | Citations (PDF) |
| 400 | Anticytomegalovirus seropositivity in rheumatoid arthritis is not associated with the presence of severe extraarticular complications: Comment on the article by Pierer et al | 6.1 | 1 | Citations (PDF) |
| 401 | The additive value of magnetic resonance imaging for bone edema in predicting rheumatoid arthritis development in early undifferentiated arthritis: Comment on the article by Duer-Jensen et al | 6.1 | 3 | Citations (PDF) |
| 402 | Risk of alanine transferase (ALT) elevation in patients with rheumatoid arthritis treated with methotrexate in a DAS-steered strategy | 2.2 | 28 | Citations (PDF) |
| 403 | Anti-citrullinated protein antibodies (ACPA) in early rheumatoid arthritis | 1.9 | 15 | Citations (PDF) |
| 404 | Do knee abnormalities visualised on MRI explain knee pain in knee osteoarthritis? A systematic review | 6.9 | 355 | Citations (PDF) |
| 405 | Predicting arthritis outcomes--what can be learned from the Leiden Early Arthritis Clinic? | 1.9 | 267 | Citations (PDF) |
| 406 | Discontinuing treatment in patients with rheumatoid arthritis in sustained clinical remission: exploratory analyses from the BeSt study | 6.9 | 147 | Citations (PDF) |
| 407 | The impact of four dynamic, goal-steered treatment strategies on the 5-year outcomes of rheumatoid arthritis patients in the BeSt study | 6.9 | 167 | Citations (PDF) |
| 408 | A decrease in disease activity score (DAS) level is associated with a decrease in health assessment questionnaire (HAQ) score, independent of follow-up duration, during 5 years of tightly controlled treatment: results from the BeSt study | 6.9 | 21 | Citations (PDF) |
| 409 | Animal models for arthritis: innovative tools for prevention and treatment | 6.9 | 108 | Citations (PDF) |
| 410 | Increased incidence of pregnancy complications in women who later develop scleroderma: a case control study | 3.9 | 35 | Citations (PDF) |
| 411 | Can anti-cyclic citrullinated peptide antibody-negative RA be subdivided into clinical subphenotypes? | 3.9 | 21 | Citations (PDF) |
| 412 | Discontinuation of infliximab and potential predictors of persistent low disease activity in patients with early rheumatoid arthritis and disease activity score-steered therapy: subanalysis of the BeSt study | 6.9 | 107 | Citations (PDF) |
| 413 | Treatment strategies in recent onset rheumatoid arthritis | 3.6 | 13 | Citations (PDF) |
| 414 | Drug-free remission: is it already possible? | 3.6 | 24 | Citations (PDF) |
| 415 | Variants of gene for microsomal prostaglandin E2 synthase show association with disease and severe inflammation in rheumatoid arthritis | 3.0 | 16 | Citations (PDF) |
| 416 | Body mass index and alignment and their interaction as risk factors for progression of knees with radiographic signs of osteoarthritis | 5.5 | 50 | Citations (PDF) |
| 417 | Validity of joint space width measurements in hand osteoarthritis | 5.5 | 20 | Citations (PDF) |
| 418 | Genetics of rheumatoid arthritis: what have we learned? | 2.8 | 151 | Citations (PDF) |
| 419 | The fine specificity of IgM anti-citrullinated protein antibodies (ACPA) is different from that of IgG ACPA | 3.9 | 19 | Citations (PDF) |
| 420 | Changes in hand bone mineral density and the association with the level of disease activity in patients with rheumatoid arthritis: Bone mineral density measurements in a multicenter randomized clinical trial | 2.8 | 26 | Citations (PDF) |
| 421 | Classification of rheumatoid arthritis: Comparison of the 1987 American College of Rheumatology criteria and the 2010 American College of Rheumatology/European League Against Rheumatism criteria | 6.1 | 240 | Citations (PDF) |
| 422 | The interaction between HLA shared epitope alleles and smoking and its contribution to autoimmunity against several citrullinated antigens | 6.1 | 60 | Citations (PDF) |
| 423 | Baseline serum adipokine levels predict radiographic progression in early rheumatoid arthritis | 6.1 | 106 | Citations (PDF) |
| 424 | Recommendations for publication of genetic association studies inArthritis & Rheumatism | 6.1 | 19 | Citations (PDF) |
| 425 | Left ventricular dysfunction assessed by speckle-tracking strain analysis in patients with systemic sclerosis: Relationship to functional capacity and ventricular arrhythmias | 6.1 | 88 | Citations (PDF) |
| 426 | State of the art lecture: IP53. Inflammatory Arthritis: Prospects for Next Decade | 1.9 | 0 | Citations (PDF) |
| 427 | Reliability, sensitivity to change and feasibility of three radiographic scoring methods for hand osteoarthritis | 6.9 | 23 | Citations (PDF) |
| 428 | PADI4 polymorphism predisposes male smokers to rheumatoid arthritis | 6.9 | 60 | Citations (PDF) |
| 429 | The window of opportunity in ACPA-positive rheumatoid arthritis is not explained by ACPA characteristics | 6.9 | 6 | Citations (PDF) |
| 430 | The development of a simple questionnaire to screen patients with SLE for the presence of neuropsychiatric symptoms in routine clinical practice | 1.7 | 14 | Citations (PDF) |
| 431 | Association between leptin, adiponectin and resistin and long-term progression of hand osteoarthritis | 6.9 | 134 | Citations (PDF) |
| 432 | Osteophytes and joint space narrowing are independently associated with pain in finger joints in hand osteoarthritis | 6.9 | 72 | Citations (PDF) |
| 433 | Anti-cyclic citrullinated peptide antibodies are a collection of anti-citrullinated protein antibodies and contain overlapping and non-overlapping reactivities | 6.9 | 127 | Citations (PDF) |
| 434 | Which elements of the criteria for RA are stable over time? | 1.9 | 1 | Citations (PDF) |
| 435 | Simplified versions of the original disease activity score: validation in the BeSt trial | 6.9 | 6 | Citations (PDF) |
| 436 | Association with joint damage and physical functioning of nine composite indices and the 2011 ACR/EULAR remission criteria in rheumatoid arthritis | 6.9 | 95 | Citations (PDF) |
| 437 | Autoantibodies recognizing carbamylated proteins are present in sera of patients with rheumatoid arthritis and predict joint damage | 7.5 | 536 | Citations (PDF) |
| 438 | Health care usage in Dutch systemic lupus erythematosus patientsLupus, 2011, 20, 1147-1154 | 1.7 | 4 | Citations (PDF) |
| 439 | Distinct ACPA fine specificities, formed under the influence of HLA shared epitope alleles, have no effect on radiographic joint damage in rheumatoid arthritis | 6.9 | 47 | Citations (PDF) |
| 440 | Anti-citrullinated protein antibodies have a low avidity compared with antibodies against recall antigens | 6.9 | 76 | Citations (PDF) |
| 441 | Meta-Analysis of Genome-Wide Association Studies in Celiac Disease and Rheumatoid Arthritis Identifies Fourteen Non-HLA Shared Loci | 3.2 | 335 | Citations (PDF) |
| 442 | Determinants of absence of osteoarthritis in old age | 1.4 | 40 | Citations (PDF) |
| 443 | Clinical and radiographic disease course of hand osteoarthritis and determinants of outcome after 6 years | 6.9 | 79 | Citations (PDF) |
| 444 | Systemic and local factors are involved in the evolution of erosions in hand osteoarthritis | 6.9 | 28 | Citations (PDF) |
| 445 | A comparison between the simplified erosion and narrowing score and the Sharp–van der Heijde score: post hoc analysis from the BeSt study | 6.9 | 12 | Citations (PDF) |
| 446 | Limitations in daily activities are the major determinant of reduced health-related quality of life in patients with hand osteoarthritis | 6.9 | 90 | Citations (PDF) |
| 447 | Association between Several Clinical and Radiological Determinants with Long-Term Clinical Progression and Good Prognosis of Lower Limb Osteoarthritis | 2.3 | 23 | Citations (PDF) |
| 448 | Low innate production of interleukin-1β and interleukin-6 is associated with the absence of osteoarthritis in old age | 5.5 | 72 | Citations (PDF) |
| 449 | Treatment with TNF-α inhibitor infliximab might reduce hand osteoarthritis in patients with rheumatoid arthritis | 5.5 | 73 | Citations (PDF) |
| 450 | Neutralization of IL-4 reverses the nonresponsiveness of CD4+ T cells to regulatory T-cell induction in non-responder mouse strains | 2.2 | 8 | Citations (PDF) |
| 451 | DX5 + CD4 + T cells modulate cytokine production by CD4 + T cells towards IL‐10 via the production of IL‐4 | 3.1 | 5 | Citations (PDF) |
| 452 | Validity of the disease activity score in undifferentiated arthritis | 2.8 | 7 | Citations (PDF) |
| 453 | Identification of citrullinated vimentin peptides as T cell epitopes in HLA–DR4–positive patients with rheumatoid arthritis | 6.1 | 106 | Citations (PDF) |
| 454 | Protection against anti–citrullinated protein antibody–positive rheumatoid arthritis is predominantly associated with HLA–DRB1*1301: A meta‐analysis of HLA–DRB1 associations with anti–citrullinated protein antibody–positive and anti–citrullinated protein antibody–negative rheumatoid arthritis in four European populations | 6.1 | 144 | Citations (PDF) |
| 455 | Glycan profiling of anti–citrullinated protein antibodies isolated from human serum and synovial fluid | 6.1 | 204 | Citations (PDF) |
| 456 | Rheumatoid arthritis risk allele PTPRC is also associated with response to anti–tumor necrosis factor α therapy | 6.1 | 121 | Citations (PDF) |
| 457 | The 2010 American College of Rheumatology/European League Against Rheumatism classification criteria for rheumatoid arthritis: Phase 2 methodological report | 6.1 | 272 | Citations (PDF) |
| 458 | 2010 Rheumatoid arthritis classification criteria: An American College of Rheumatology/European League Against Rheumatism collaborative initiative | 6.1 | 8,257 | Citations (PDF) |
| 459 | Long‐term impact of delay in assessment of patients with early arthritis | 6.1 | 425 | Citations (PDF) |
| 460 | Tract‐based spatial statistics on diffusion tensor imaging in systemic lupus erythematosus reveals localized involvement of white matter tracts | 6.1 | 53 | Citations (PDF) |
| 461 | Genome-wide association study meta-analysis identifies seven new rheumatoid arthritis risk loci | 25.2 | 1,198 | Citations (PDF) |
| 462 | Gene-environment interaction influences the reactivity of autoantibodies to citrullinated antigens in rheumatoid arthritis | 25.2 | 71 | Citations (PDF) |
| 463 | Rheumatoid Arthritis | 9.6 | 43 | Citations (PDF) |
| 464 | Epitope spreading of the anti-citrullinated protein antibody response occurs before disease onset and is associated with the disease course of early arthritis | 6.9 | 293 | Citations (PDF) |
| 465 | The PTPN22 susceptibility risk variant is not associated with the rate of joint destruction in anti-citrullinated protein antibody-positive rheumatoid arthritis | 6.9 | 4 | Citations (PDF) |
| 466 | Repair of joint erosions in rheumatoid arthritis: prevalence and patient characteristics in a large inception cohort | 6.9 | 41 | Citations (PDF) |
| 467 | How to avoid phenotypic misclassification in using joint destruction as an outcome measure for rheumatoid arthritis? | 1.9 | 12 | Citations (PDF) |
| 468 | The ACPA isotype profile reflects long-term radiographic progression in rheumatoid arthritis | 6.9 | 71 | Citations (PDF) |
| 469 | Clinical burden of erosive hand osteoarthritis and its relationship to nodes | 6.9 | 70 | Citations (PDF) |
| 470 | Thumb base involvement in symptomatic hand osteoarthritis is associated with more pain and functional disability | 6.9 | 119 | Citations (PDF) |
| 471 | Prevention of autoimmune rheumatic disease: state of the art and future perspectives | 6.9 | 94 | Citations (PDF) |
| 472 | Genetic variants in the prediction of rheumatoid arthritis | 6.9 | 47 | Citations (PDF) |
| 473 | Evidence for treating rheumatoid arthritis to target: results of a systematic literature search | 6.9 | 214 | Citations (PDF) |
| 474 | Improved treatment strategies reduce the increased mortality risk in early RA patients | 1.9 | 57 | Citations (PDF) |
| 475 | Loss of imprinting of IGF2 characterises high IGF2 mRNA-expressing type of fibroblast-like synoviocytes in rheumatoid arthritis | 6.9 | 11 | Citations (PDF) |
| 476 | Blood pressure changes in patients with recent-onset rheumatoid arthritis treated with four different treatment strategies: a post hoc analysis from the BeSt trial | 6.9 | 59 | Citations (PDF) |
| 477 | Diagnostic value of anti-MCV antibodies in differentiating early inflammatory arthritis | 6.9 | 62 | Citations (PDF) |
| 478 | Current evidence for a strategic approach to the management of rheumatoid arthritis with disease-modifying antirheumatic drugs: a systematic literature review informing the EULAR recommendations for the management of rheumatoid arthritis | 6.9 | 132 | Citations (PDF) |
| 479 | Disease Activity Monitoring in Rheumatoid Arthritis in Daily Practice: Experiences with METEOR, a Free Online Tool | 2.3 | 11 | Citations (PDF) |
| 480 | Antibodies toPorphyromonas gingivalisAre Associated with Anticitrullinated Protein Antibodies in Patients with Rheumatoid Arthritis and Their Relatives | 2.3 | 212 | Citations (PDF) |
| 481 | The TRAF1-C5 region on chromosome 9q33 is associated with multiple autoimmune diseases | 6.9 | 52 | Citations (PDF) |
| 482 | Pain in hand osteoarthritis is associated with inflammation: the value of ultrasound | 6.9 | 120 | Citations (PDF) |
| 483 | Association of the 6q23 region with the rate of joint destruction in rheumatoid arthritis | 6.9 | 33 | Citations (PDF) |
| 484 | The joint–gut axis in inflammatory bowel diseases | 1.3 | 124 | Citations (PDF) |
| 485 | EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs | 6.9 | 1,498 | Citations (PDF) |
| 486 | A matrix risk model for the prediction of rapid radiographic progression in patients with rheumatoid arthritis receiving different dynamic treatment strategies: post hoc analyses from the BeSt study | 6.9 | 188 | Citations (PDF) |
| 487 | Clinical synovitis in a particular joint is associated with progression of erosions and joint space narrowing in that same joint, but not in patients initially treated with infliximab | 6.9 | 43 | Citations (PDF) |
| 488 | Adoptive transfer of IL-10-secreting CD4+CD49b+ regulatory T cells suppresses ongoing arthritis | 6.6 | 29 | Citations (PDF) |
| 489 | Rheumatoid arthritis | 62.1 | 3,052 | Citations (PDF) |
| 490 | TRAF1/C5polymorphism is not associated with increased mortality in rheumatoid arthritis: two large longitudinal studies | 3.9 | 17 | Citations (PDF) |
| 491 | 2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative | 6.9 | 3,794 | Citations (PDF) |
| 492 | Survival, comorbidities and joint damage 11 years after the COBRA combination therapy trial in early rheumatoid arthritis | 6.9 | 104 | Citations (PDF) |
| 493 | Recent advances in the management of rheumatoid arthritis | 0.1 | 56 | Citations (PDF) |
| 494 | Association of IL2RA and IL2RB with rheumatoid arthritis: a replication study in a Dutch population | 6.9 | 28 | Citations (PDF) |
| 495 | Residual inflammation after rituximab treatment is associated with sustained synovial plasma cell infiltration and enhanced B cell repopulation | 6.9 | 84 | Citations (PDF) |
| 496 | Criteria for the selection of single nucleotide polymorphisms in pathway pharmacogenetics: TNF inhibitors as a case study | 6.6 | 9 | Citations (PDF) |
| 497 | The use of data from early arthritis clinics for clinical research | 3.9 | 10 | Citations (PDF) |
| 498 | DC‐induced CD8+ T‐cell response is inhibited by MHC class II‐dependent DX5+CD4+ Treg | 3.1 | 9 | Citations (PDF) |
| 499 | Quantitative heritability of anti–citrullinated protein antibody–positive and anti–citrullinated protein antibody–negative rheumatoid arthritis | 6.1 | 229 | Citations (PDF) |
| 500 | Confirmation of STAT4, IL2/IL21, and CTLA4 polymorphisms in rheumatoid arthritis | 6.1 | 93 | Citations (PDF) |
| 501 | Efficacy of intraarticular infliximab in patients with chronic or recurrent gonarthritis: A clinical randomized trial | 5.7 | 31 | Citations (PDF) |
| 502 | Anti–cyclic citrullinated peptide antibodies from rheumatoid arthritis patients activate complement via both the classical and alternative pathways | 6.1 | 235 | Citations (PDF) |
| 503 | Prevalence of and predictive factors for sustained disease‐modifying antirheumatic drug–free remission in rheumatoid arthritis: Results from two large early arthritis cohorts | 6.1 | 206 | Citations (PDF) |
| 504 | Illness perceptions in patients with osteoarthritis: Change over time and association with disability | 5.7 | 107 | Citations (PDF) |
| 505 | Value of anti–modified citrullinated vimentin and third‐generation anti–cyclic citrullinated peptide compared with second‐generation anti–cyclic citrullinated peptide and rheumatoid factor in predicting disease outcome in undifferentiated arthritis and rheumatoid arthritis | 6.1 | 145 | Citations (PDF) |
| 506 | Association of a single‐nucleotide polymorphism in CD40 with the rate of joint destruction in rheumatoid arthritis | 6.1 | 99 | Citations (PDF) |
| 507 | Brain involvement in rheumatoid arthritis: A magnetic resonance spectroscopy study | 6.1 | 23 | Citations (PDF) |
| 508 | Variation in IL7R predisposes to sarcoid inflammation | 3.8 | 41 | Citations (PDF) |
| 509 | Genetic variants at CD28, PRDM1 and CD2/CD58 are associated with rheumatoid arthritis risk | 25.2 | 331 | Citations (PDF) |
| 510 | Contribution of Fcγ receptor IIIA gene 158V/F polymorphism and copy number variation to the risk of ACPA-positive rheumatoid arthritis | 6.9 | 45 | Citations (PDF) |
| 511 | The prognostic value of baseline erosions in undifferentiated arthritis | 3.9 | 44 | Citations (PDF) |
| 512 | Optimalisation of the clinical pharmacogenetic model to predict methotrexate treatment response: the influence of the number of haplotypes of MTHFR 1298A–677C alleles on probability to respond | 6.9 | 9 | Citations (PDF) |
| 513 | The BeSt story: on strategy trials in rheumatoid arthritis | 3.6 | 40 | Citations (PDF) |
| 514 | A european perspective on the 50th anniversary ofArthritis & Rheumatism | 6.1 | 0 | Citations (PDF) |
| 515 | Differences in synovial tissue infiltrates between anti–cyclic citrullinated peptide–positive rheumatoid arthritis and anti–cyclic citrullinated peptide–negative rheumatoid arthritis | 6.1 | 136 | Citations (PDF) |
| 516 | Suppressor activity among CD4+,CD25++ T cells is discriminated by membrane‐bound tumor necrosis factor α | 6.1 | 25 | Citations (PDF) |
| 517 | Reply | 6.1 | 0 | Citations (PDF) |
| 518 | The inflammatory disease–associated variants in IL12B and IL23R are not associated with rheumatoid arthritis | 6.1 | 41 | Citations (PDF) |
| 519 | Validation of a prediction rule for disease outcome in patients with recent‐onset undifferentiated arthritis: Moving toward individualized treatment decision‐making | 6.1 | 155 | Citations (PDF) |
| 520 | Marked differences in fine specificity and isotype usage of the anti–citrullinated protein antibody in health and disease | 6.1 | 159 | Citations (PDF) |
| 521 | Common variants at CD40 and other loci confer risk of rheumatoid arthritis | 25.2 | 503 | Citations (PDF) |
| 522 | Translating basic research into clinical rheumatology | 3.9 | 6 | Citations (PDF) |
| 523 | Advances in the genetics of rheumatoid arthritis point to subclassification into distinct disease subsets | 3.9 | 137 | Citations (PDF) |
| 524 | Hyperpigmentation of the skin due to hydroxychloroquine | 1.4 | 23 | Citations (PDF) |
| 525 | Gene Therapy and Cement Injection for Restabilization of Loosened Hip Prostheses | 3.2 | 27 | Citations (PDF) |
| 526 | A high body mass index has a protective effect on the amount of joint destruction in small joints in early rheumatoid arthritis | 6.9 | 159 | Citations (PDF) |
| 527 | Leflunomide and methotrexate reduce levels of activated matrix metalloproteinases in complexes with α2 macroglobulin in serum of rheumatoid arthritis patients | 6.9 | 20 | Citations (PDF) |
| 528 | Pretreatment serum levels of anti-cyclic citrullinated peptide antibodies are associated with the response to methotrexate in recent-onset arthritis | 6.9 | 37 | Citations (PDF) |
| 529 | Innate production of tumour necrosis factor α and interleukin 10 is associated with radiological progression of knee osteoarthritis | 6.9 | 53 | Citations (PDF) |
| 530 | Lupus and the central nervous system | 1.7 | 19 | Citations (PDF) |
| 531 | Gene Therapy for the Treatment of Hip Prosthesis Loosening: Adverse Events in a Phase 1 Clinical Study | 3.2 | 7 | Citations (PDF) |
| 532 | Assistive devices: usage in patients with rheumatoid arthritis | 2.2 | 52 | Citations (PDF) |
| 533 | A Large-Scale Rheumatoid Arthritis Genetic Study Identifies Association at Chromosome 9q33.2 | 3.2 | 78 | Citations (PDF) |
| 534 | Risk of progression from undifferentiated arthritis to rheumatoid arthritis: the effect of the PTPN22 1858T-allele in anti-citrullinated peptide antibody positive patients | 1.9 | 44 | Citations (PDF) |
| 535 | A Candidate Gene Approach Identifies the TRAF1/C5 Region as a Risk Factor for Rheumatoid Arthritis | 8.0 | 240 | Citations (PDF) |
| 536 | Protective effect of noninherited maternal HLA-DR antigens on rheumatoid arthritis development | 7.5 | 61 | Citations (PDF) |
| 537 | Recent insights in the pharmacological actions of methotrexate in the treatment of rheumatoid arthritis | 1.9 | 299 | Citations (PDF) |
| 538 | Differential responsiveness to immunoablative therapy in refractory rheumatoid arthritis is associated with level and avidity of anti-cyclic citrullinated protein autoantibodies: a case study | 3.9 | 11 | Citations (PDF) |
| 539 | Exploratory analysis of four polymorphisms in humanGGHandFPGSgenes and their effect in methotrexate-treated rheumatoid arthritis patients | 1.5 | 59 | Citations (PDF) |
| 540 | The HLA–DRB1 shared epitope alleles differ in the interaction with smoking and predisposition to antibodies to cyclic citrullinated peptide | 6.1 | 126 | Citations (PDF) |
| 541 | A prediction rule for disease outcome in patients with Recent-onset undifferentiated arthritis: How to guide individual treatment decisions | 6.1 | 339 | Citations (PDF) |
| 542 | Reply | 6.1 | 1 | Citations (PDF) |
| 543 | Efficacy of methotrexate treatment in patients with probable rheumatoid arthritis: A double-blind, randomized, placebo-controlled trial | 6.1 | 385 | Citations (PDF) |
| 544 | A clinical pharmacogenetic model to predict the efficacy of methotrexate monotherapy in recent-onset rheumatoid arthritis | 6.1 | 236 | Citations (PDF) |
| 545 | Emerging patterns of risk factor make-up enable subclassification of rheumatoid arthritis | 6.1 | 45 | Citations (PDF) |
| 546 | Inflammation and ectopic lymphoid structures in rheumatoid arthritis synovial tissues dissected by genomics technology: Identification of the interleukin‐7 signaling pathway in tissues with lymphoid neogenesis | 6.1 | 164 | Citations (PDF) |
| 547 | Association of smoking with the constitution of the anti–cyclic citrullinated peptide response in the absence of HLA–DRB1 shared epitope alleles | 6.1 | 38 | Citations (PDF) |
| 548 | Immunohistochemical analysis as a means to predict responsiveness to rituximab treatment | 6.1 | 159 | Citations (PDF) |
| 549 | Transient expression of FOXP3 in human activated nonregulatory CD4 + T cells | 3.1 | 967 | Citations (PDF) |
| 550 | Engraftment of cutaneous fibroblasts within synovial membrane in a nonhuman primate: Short-term results | 2.2 | 10 | Citations (PDF) |
| 551 | Potential role of pharmacogenetics in anti-TNF treatment of rheumatoid arthritis and Crohn's disease | 6.6 | 57 | Citations (PDF) |
| 552 | Title is missing! | 3.9 | 89 | Citations (PDF) |
| 553 | Title is missing! | 3.9 | 42 | Citations (PDF) |
| 554 | Title is missing! | 3.9 | 45 | Citations (PDF) |
| 555 | Murine Fc receptors for IgG are redundant in facilitating presentation of immune complex derived antigen to CD8+ T cells in vivo | 2.2 | 32 | Citations (PDF) |
| 556 | HLA and RA Revisited: Citrullinated Food for the SE Hypothesis, the DR6 Effect, and NIMA | 1.0 | 16 | Citations (PDF) |
| 557 | Dendritic cells, but not macrophages or B cells, activate major histocompatibility complex class II-restricted CD4+T cells upon immune-complex uptake in vivo | 4.7 | 60 | Citations (PDF) |
| 558 | Arthrographies au cours des prothèses de hanche descellées. Évaluation des possibilités thérapeutiques intra-articulaires | 0.0 | 0 | Citations (PDF) |
| 559 | Genetic markers of treatment response in rheumatoid arthritis | 4.0 | 13 | Citations (PDF) |
| 560 | Arthrography in loosened hip prostheses. Assessment of possibilities for intra-articular therapy | 2.2 | 4 | Citations (PDF) |
| 561 | Activation of receptor for advanced glycation end products in osteoarthritis leads to increased stimulation of chondrocytes and synoviocytes | 6.1 | 139 | Citations (PDF) |
| 562 | Pulmonary fibrosis in a patient with rheumatoid arthritis treated with adalimumab | 6.1 | 75 | Citations (PDF) |
| 563 | Efficacy and toxicity of methotrexate in early rheumatoid arthritis are associated with single-nucleotide polymorphisms in genes coding for folate pathway enzymes | 6.1 | 199 | Citations (PDF) |
| 564 | The HLA–DRB1 shared epitope alleles are primarily a risk factor for anti–cyclic citrullinated peptide antibodies and are not an independent risk factor for development of rheumatoid arthritis | 6.1 | 311 | Citations (PDF) |
| 565 | Variation in radiologic joint destruction in rheumatoid arthritis differs between monozygotic and dizygotic twins and pairs of unrelated patients | 6.1 | 29 | Citations (PDF) |
| 566 | Relationship between genetic variants in the adenosine pathway and outcome of methotrexate treatment in patients with recent-onset rheumatoid arthritis | 6.1 | 126 | Citations (PDF) |
| 567 | Reply | 6.1 | 0 | Citations (PDF) |
| 568 | Isotype distribution of ANTI–CYCLIC citrullinated peptide antibodies in undifferentiated arthritis and rheumatoid arthritis reflects an ongoing immune response | 6.1 | 194 | Citations (PDF) |
| 569 | Detection of change in CNS involvement in neuropsychiatric SLE: A magnetization transfer study | 3.4 | 35 | Citations (PDF) |
| 570 | The 620W allele is the PTPN22 genetic variant conferring susceptibility to RA in a Dutch population | 1.9 | 34 | Citations (PDF) |
| 571 | Selective Involvement of the Amygdala in Systemic Lupus Erythematosus | 8.0 | 58 | Citations (PDF) |
| 572 | How evidence-based are advertisements in journals regarding the subspecialty of rheumatology? | 1.9 | 22 | Citations (PDF) |
| 573 | Tumor Necrosis Factor-α Genetic Predisposing Factors Can Influence Clinical Severity in Nephropathia Epidemica | 1.1 | 36 | Citations (PDF) |
| 574 | The RAGE G82S polymorphism is not associated with rheumatoid arthritis independently of HLA-DRB1*0401 | 1.9 | 13 | Citations (PDF) |
| 575 | Understanding the genetic contribution to rheumatoid arthritis | 3.6 | 100 | Citations (PDF) |
| 576 | Control of systemic B cell-mediated autoimmune disease by nonmyeloablative conditioning and major histocompatibility complex-mismatched allogeneic bone marrow transplantationBlood, 2005, 105, 2991-2994 | 4.8 | 12 | Citations (PDF) |
| 577 | Reply | 6.1 | 3 | Citations (PDF) |
| 578 | Association of the risk of osteoarthritis with high innate production of interleukin-1β and low innate production of interleukin-10 ex vivo, upon lipopolysaccharide stimulation | 6.1 | 53 | Citations (PDF) |
| 579 | Invasiveness of fibroblast-like synoviocytes is an individual patient characteristic associated with the rate of joint destruction in patients with rheumatoid arthritis | 6.1 | 138 | Citations (PDF) |
| 580 | An independent role of protective HLA class II alleles in rheumatoid arthritis severity and susceptibility | 6.1 | 114 | Citations (PDF) |
| 581 | Association of HLA-DR3 with anti-cyclic citrullinated peptide antibody-negative rheumatoid arthritis | 6.1 | 166 | Citations (PDF) |
| 582 | Refining the complex rheumatoid arthritis phenotype based on specificity of the HLA–DRB1 shared epitope for antibodies to citrullinated proteins | 6.1 | 526 | Citations (PDF) |
| 583 | CTLA4 is differentially associated with autoimmune diseases in the Dutch population | 2.9 | 65 | Citations (PDF) |
| 584 | A role for mannose-binding lectin dysfunction in generation of autoantibodies in systemic lupus erythematosus | 2.1 | 54 | Citations (PDF) |
| 585 | RUNX1 intronic SNP is not associated with rheumatoid arthritis susceptibility in Dutch Caucasians | 1.9 | 3 | Citations (PDF) |
| 586 | Early aggressive therapy in rheumatoid arthritis: a 'window of opportunity'? | 4.8 | 17 | Citations (PDF) |
| 587 | Bilateral hydropneumothoraces in a patient with pulmonary rheumatoid nodules during treatment with methotrexate | 6.9 | 4 | Citations (PDF) |
| 588 | Redefining the HLA and RA association: To be or not to be anti-CCP positive | 6.6 | 78 | Citations (PDF) |
| 589 | Elevated formation of pyridinoline cross-links by profibrotic cytokines is associated with enhanced lysyl hydroxylase 2b levels | 4.1 | 98 | Citations (PDF) |
| 590 | The type of collagen cross-link determines the reversibility of experimental skin fibrosis | 4.1 | 137 | Citations (PDF) |
| 591 | IL-10 and toll-like receptor-4 polymorphisms and the in vivo and ex vivo response to endotoxin | 3.5 | 41 | Citations (PDF) |
| 592 | Antibodies to citrullinated proteins and differences in clinical progression of rheumatoid arthritis | 3.9 | 429 | Citations (PDF) |
| 593 | Transcription of the IL10 gene reveals allele-specific regulation at the mRNA level | 2.9 | 252 | Citations (PDF) |
| 594 | Functional regulatory immune responses against human cartilage glycoprotein-39 in health vs. proinflammatory responses in rheumatoid arthritis | 7.5 | 77 | Citations (PDF) |
| 595 | Efficacy of UVA-1 cold light as an adjuvant therapy for systemic lupus erythematosus | 2.1 | 38 | Citations (PDF) |
| 596 | Interleukin-10 promoter single-nucleotide polymorphisms as markers for disease susceptibility and disease severity in leprosy | 3.8 | 69 | Citations (PDF) |
| 597 | Impaired innate immunity predicts frailty in old age. The Leiden 85-plus study | 3.7 | 108 | Citations (PDF) |
| 598 | Association of autoantibodies to glucose-6-phosphate isomerase with extraarticular complications in rheumatoid arthritis | 6.1 | 70 | Citations (PDF) |
| 599 | Association of the interleukin-1 gene cluster with radiographic signs of osteoarthritis of the hip | 6.1 | 101 | Citations (PDF) |
| 600 | Association between HLA class II genes and autoantibodies to cyclic citrullinated peptides (CCPs) influences the severity of rheumatoid arthritis | 6.1 | 337 | Citations (PDF) |
| 601 | Antigen-specific immunomodulation of collagen-induced arthritis with tumor necrosis factor-stimulated dendritic cells | 6.1 | 63 | Citations (PDF) |
| 602 | Increased formation of pyridinoline cross-links due to higher telopeptide lysyl hydroxylase levels is a general fibrotic phenomenon | 4.5 | 203 | Citations (PDF) |
| 603 | Title is missing! | 2.1 | 77 | Citations (PDF) |
| 604 | Interleukin–10 promoter haplotypes are differently distributed in the Brazilian versus the Dutch population | 2.8 | 51 | Citations (PDF) |
| 605 | Evidence for non-random distribution of Fcγ receptor genotype combinations | 2.8 | 57 | Citations (PDF) |
| 606 | Genetics in rheumatoid arthritis | 3.9 | 15 | Citations (PDF) |
| 607 | High innate production of interleukin-10 and tumor necrosis factor-α contributes to susceptibility for non-paraneoplastic Lambert–Eaton myasthenic syndrome | 2.3 | 18 | Citations (PDF) |
| 608 | Analysis of allelic expression patterns of IL-2, IL-3, IL-4, and IL-13 in human CD4+ T cell clones | 3.1 | 8 | Citations (PDF) |
| 609 | Fibroblast-like synoviocytes from rheumatoid arthritis patients express less FLICE-inhibitory protein than fibroblast-like synoviocytes from trauma patients: Comment on the article by Schedel et al | 6.1 | 3 | Citations (PDF) |
| 610 | Association between polymorphisms in the human chemokine receptor genes CCR2 and CX3
CR1 and rheumatoid arthritis | 0.6 | 14 | Citations (PDF) |
| 611 | Autoantibodies against mannose-binding lectin in systemic lupus erythematosus | 3.3 | 58 | Citations (PDF) |
| 612 | Discovery of distinctive gene expression profiles in rheumatoid synovium using cDNA microarray technology: evidence for the existence of multiple pathways of tissue destruction and repair | 3.8 | 322 | Citations (PDF) |
| 613 | Association of polymorphisms of the tumour necrosis factor receptors I and II and rheumatoid arthritis | 2.1 | 12 | Citations (PDF) |
| 614 | Identification of PLOD2 as Telopeptide Lysyl Hydroxylase, an Important Enzyme in Fibrosis | 2.2 | 378 | Citations (PDF) |
| 615 | Evidence for additional genetic risk indicators of relapse-onset MS within the HLA region | 1.0 | 54 | Citations (PDF) |
| 616 | Elevated IL-16 levels in patients with systemic lupus erythematosus are associated with disease severity but not with genetic susceptibility to lupus | 1.7 | 47 | Citations (PDF) |
| 617 | Tumor Necrosis Factor-α +489G/A gene polymorphism is associated with chronic obstructive pulmonary disease | 4.2 | 63 | Citations (PDF) |
| 618 | Frequency of functional interleukin-10 promoter polymorphism is different between relapse-onset and primary progressive multiple sclerosis | 1.0 | 49 | Citations (PDF) |
| 619 | Production of IL-1β and IL-1Ra as risk factors for susceptibility and progression of relapse-onset multiple sclerosis | 2.3 | 116 | Citations (PDF) |
| 620 | Genetic drift as an explanation for the reduced incidence of rheumatoid arthritis | 6.1 | 21 | Citations (PDF) |
| 621 | The R-H polymorphism of FC? receptor IIa as a risk factor for systemic lupus erythematosus is independent of single-nucleotide polymorphisms in the interleukin-10 gene promoter | 6.1 | 22 | Citations (PDF) |
| 622 | Genetics in rheumatoid arthritis | 4.0 | 4 | Citations (PDF) |
| 623 | Polymorphisms in or near tumour necrosis factor (TNF)-gene do not determine levels of endotoxin-induced TNF production | 3.8 | 50 | Citations (PDF) |
| 624 | FUNCTIONAL ANALYSIS OF LINKER-SCAN MUTANTS SPANNING THE −376, −308, −244, AND −238 POLYMORPHIC SITES OF THE TNF-α PROMOTER | 3.5 | 117 | Citations (PDF) |
| 625 | Imaging modalities in central nervous system systemic lupus erythematosus | 3.6 | 48 | Citations (PDF) |
| 626 | The influence of synovial fluid on adenovirus-mediated gene transfer to the synovial tissue | 6.1 | 36 | Citations (PDF) |
| 627 | Infection efficiency of type 5 adenoviral vectors in synovial tissue can be enhanced with a type 16 fiber | 6.1 | 41 | Citations (PDF) |
| 628 | Effect of folic or folinic acid supplementation on the toxicity and efficacy of methotrexate in rheumatoid arthritis: A forty-eight-week, multicenter, randomized, double-blind, placebo-controlled study | 6.1 | 389 | Citations (PDF) |
| 629 | The C677T mutation in the methylenetetrahydrofolate reductase gene: A genetic risk factor for methotrexate-related elevation of liver enzymes in rheumatoid arthritis patients | 6.1 | 188 | Citations (PDF) |
| 630 | Optimizing human fertility and survival | 33.0 | 83 | Citations (PDF) |
| 631 | Allele-specific quantification of tumor necrosis factor α (TNF) transcription and the role of promoter polymorphisms in rheumatoid arthritis patients and healthy individuals | 3.8 | 86 | Citations (PDF) |
| 632 | Six microsatellite markers on the short arm of chromosome 6 in relation to HLA-DR3 and TNF−308A in systemic lupus erythematosus | 3.8 | 51 | Citations (PDF) |
| 633 | Relevance of Fcγ Receptor and Interleukin‐10 Polymorphisms for Meningococcal Disease | 3.7 | 104 | Citations (PDF) |
| 634 | Innate production of interleukin-10 and tumor necrosis factor affects the risk of multiple sclerosis | 6.6 | 47 | Citations (PDF) |
| 635 | CNS involvement in primary Sjögren's syndrome: a case with a clue for the pathogenesis | 3.4 | 27 | Citations (PDF) |
| 636 | Reliability and sensitivity to change of various measures of hand function in relation to treatment of synovitis of the metacarpophalangeal joint in rheumatoid arthritis | 1.9 | 14 | Citations (PDF) |
| 637 | Low soluble FcRIII receptor demonstrates reduced neutrophil reserves in preterm neonates | 2.8 | 40 | Citations (PDF) |
| 638 | Neuropsychiatric systemic lupus erythematosus | 6.9 | 1 | Citations (PDF) |
| 639 | Feasibility of Adenovirus-Mediated Nonsurgical Synovectomy in Collagen-Induced Arthritis-Affected Rhesus Monkeys | 3.2 | 64 | Citations (PDF) |
| 640 | Association of the TNF +489 polymorphism with susceptibility and radiographic damage in rheumatoid arthritis | 3.8 | 58 | Citations (PDF) |
| 641 | Microsatellite alleles and single nucleotide polymorphisms (SNP) combine to form four major haplotype families at the human interleukin-10 (IL-10) locus | 3.8 | 211 | Citations (PDF) |
| 642 | Polymorphism within the tumor necrosis factor α (TNF) promoter region in patients with ankylosing spondylitis | 1.0 | 40 | Citations (PDF) |
| 643 | Determination of tumour necrosis factor-α and interleukin-10 production in a whole blood stimulation system: assessment of laboratory error and individual variation | 1.4 | 132 | Citations (PDF) |
| 644 | An extended HLA-DQ-DR haplotype rather than DRB1 alone contributes to RA predisposition | 2.8 | 59 | Citations (PDF) |
| 645 | Anti-C1q receptor/calreticulin autoantibodies in patients with systemic lupus erythematosus (SLE) | 3.3 | 28 | Citations (PDF) |
| 646 | Interleukin-10 microsatellite polymorphisms and IL-10 locus alleles in rheumatoid arthritis susceptibility | 62.1 | 105 | Citations (PDF) |
| 647 | Interleukin 10 secretion in relation to human IL-10 locus haplotypes | 7.5 | 463 | Citations (PDF) |
| 648 | Functional Analysis of a Human Tumor Necrosis Factor α (TNF-α) Promoter Polymorphism Related to Joint Damage in Rheumatoid Arthritis | 5.6 | 98 | Citations (PDF) |
| 649 | The effect of pentoxifylline on human neutrophil migration: A possible role for cyclic nucleotides | 5.1 | 16 | Citations (PDF) |
| 650 | Genetic influence on cytokine production and fatal meningococcal disease | 62.1 | 776 | Citations (PDF) |
| 651 | TNF-α promoter polymorphisms, production and susceptibility to multiple sclerosis in different groups of patients | 2.3 | 219 | Citations (PDF) |
| 652 | Possibility and safety of gene transfer to inflamed synovial tissue after intra-articular administration | 2.4 | 0 | Citations (PDF) |
| 653 | Clinical value of soluble IgG Fc receptor type III (sFcγRIII) in plasma from patients with neutropenia | 2.4 | 0 | Citations (PDF) |
| 654 | Allele-specific quantification of TNFA transcripts in rheumatoid arthritis | 2.9 | 16 | Citations (PDF) |
| 655 | Apoptosis of cultured rat glomerular mesangial cells induced by IgG2a monoclonal anti-Thy-1 antibodies | 5.3 | 41 | Citations (PDF) |
| 656 | Detection of a C-insertion polymorphism within the human tumor necrosis factor alpha (TNFA) gene | 2.9 | 36 | Citations (PDF) |
| 657 | Changes in Plasma FcRIII Demonstrate Increasing Receptor Production during Late Pregnancy and after Preterm Birth | 2.2 | 19 | Citations (PDF) |
| 658 | 5 Fc-gamma receptors: mediators, targets and markers of disease | 1.0 | 4 | Citations (PDF) |
| 659 | Reactivity of cloned, expressed human FcγRIII isoforms with monoclonal antibodies which distinguish cell-type-specific and allelic forms of FcγRIII | 3.1 | 32 | Citations (PDF) |
| 660 | The Pi-linked receptor FcRIII is released on stimulation of neutrophils | 37.9 | 397 | Citations (PDF) |
| 661 | B-cell receptor sequencing of anti-citrullinated protein antibody (ACPA) IgG-expressing B cells indicates a selective advantage for the introduction of N-glycosylation sites during somatic hypermutation | 6.9 | 70 | Citations (PDF) |
| 662 | Improvement of microangiopathy after haematopoietic stem cell transplantation in systemic sclerosis | 3.1 | 2 | Citations (PDF) |
| 663 | Risk Factors for Antiphospholipid Antibodies and Antiphospholipid Syndrome | 2.5 | 2 | Citations (PDF) |
| 664 | Ratio between biological and targeted synthetic disease-modifying anti-rheumatic drugs and glucocorticoid use in various countries: results from METEOR | 1.4 | 0 | Citations (PDF) |
| 665 | A de novo dominant-negative PSMB8 mutation causes severe CANDLE/PRAAS due to arrested proteasome biogenesis | 6.9 | 5 | Citations (PDF) |
| 666 | High Interleukin-10 Production in First-Degree Relatives of Patients with Generalized but Not Cutaneous Lupus Erythematosus | 1.7 | 0 | Citations (PDF) |
| 667 | Revisiting osteoarthritis as an inflammatory disease: characterization of synovitis grading and synovial pathotypes in surgical specimens | 3.9 | 0 | Citations (PDF) |
| 668 | Symmetrical dimethylarginine as the central antigenic determinant of anti-Smith autoantibodies in systemic lupus erythematosus | 6.9 | 0 | Citations (PDF) |
